🏷

Classifications

Harrison's Chapter

Mechanistic Nosology

◈

Mechanistic Hypotheses

1

Postnatal glucose-to-fatty-acid fuel switch as the trigger for MRPL44 cardiomyopathy manifestation

nutrient_dependent_postnatal_manifestation EMERGING

Evidence balance 1 support

An emerging model proposes that ATP deficiency alone does not explain why MRPL44 hypertrophic cardiomyopathy declares itself around birth. In patient iPSC-derived cardiomyocytes, glucose-rich (fetal-like) conditions provoke a partly compensatory response - increased mtDNA copy number and mitochondrial transcription - whereas lipid-enriched (postnatal-like) conditions instead trigger the mitochondrial integrated stress response (ISRmt) with partial ER stress, lipid-droplet accumulation, and maladaptive upregulation of lipid uptake and cholesterol synthesis genes. On this model the perinatal switch to fatty-acid oxidation is the critical window that converts a compensated translation defect into hypertrophic disease. This is preprint, single-patient-line, in-vitro evidence and does NOT justify any dietary intervention.

Pathograph links

Impaired Mitochondrial Translation -> Failed Compensatory mtDNA Replication and Transcription DIRECT Cardiomyocytes respond to the translation block by amplifying mtDNA and mitochondrial transcripts, a response that cannot restore protein output. Hypothesis-tagged: rests on a single unreviewed patient iPSC-cardiomyocyte study, and a mouse NIH3T3 knockdown study found no mtDNA copy-number effect.

Failed Compensatory mtDNA Replication and Transcription -> Nutrient-Dependent Metabolic Stress Response in Cardiomyocytes DIRECT Compensation that suffices under fetal glucose-based fuel fails when the postnatal heart switches to fatty-acid oxidation.

Nutrient-Dependent Metabolic Stress Response in Cardiomyocytes -> Cardiomyocyte Bioenergetic Failure and Mitochondrial Proliferation INDIRECT KNOWN INTERMEDIATES Proposed route by which nutrient-conditional stress signaling, not ATP deficit alone, drives pathological hypertrophic growth. Intermediates: Persistent ISRmt and mTORC1-linked anabolic signaling; Lipid droplet accumulation and impaired fatty-acid utilization

Show evidence (1 reference)

DOI:10.1101/2025.09.24.678132 SUPPORT In Vitro

"These observations provide a mechanistic basis for postnatal disease manifestation and highlight nutrient metabolism as a key driver in development of infantile-onset mitochondrial hypertrophic cardiomyopathy."

States the hypothesis directly. Preprint, one patient iPSC line, awaiting peer review and replication.

?

Discussions and Knowledge Gaps

4

Why is complex IV activity disproportionately reduced relative to complex I in MRPL44 deficiency, when the measured synthesis rates of complex I and complex IV mtDNA-encoded subunits are similarly depressed and complex I has more than twice as many mtDNA-encoded subunits?

KNOWLEDGE GAP OPEN gap_disproportionate_complex_iv_deficiency

Attached to

pathophysiology#Impaired Mitochondrial Translation pathophysiology#Combined Complex I and IV Deficiency

In most mitochondrial transcription and translation defects, complex I (seven mtDNA-encoded subunits) is more affected than complex IV (three) simply through subunit stoichiometry. MRPL44 deficiency inverts this, as do LRPPRC and TACO1 disease. The 2021 functional study excluded the obvious explanation by showing that the newly synthesized complex IV subunits (MT-CO1, MT-CO2, MT-CO3) were reduced to approximately the same degree as complex I subunits (average 30.1% versus 34.3% of controls, not significantly different). A difference in post-synthetic stability of the assembled subunits was proposed but could not be excluded or confirmed. Resolving this matters because a complex IV-selective post-translational bottleneck would be a different therapeutic target from generic mitoribosome insufficiency.

Proposed experiments

Pulse-chase stability assay of mtDNA-encoded complex IV versus complex I subunits

pulse-chase protein stability assay

exp_mrpl44_cox_subunit_pulse_chase

In MRPL44-patient and isogenic corrected cardiomyocytes, perform 35S pulse-chase labelling with quantification of the decay rate of newly synthesized MT-CO1/2/3 versus MT-ND subunits, to test whether the excess complex IV deficit arises from accelerated degradation of unassembled cytochrome c oxidase subunits rather than from unequal synthesis.

Model systems

Patient iPSC-derived cardiomyocyte

MRPL44-mutant patient iPSC-derived cardiomyocytes with isogenic corrected controls, providing the human cardiac context where the biochemical defect is most severe.

OTHER

Show evidence (1 reference)

PMID:34140213 SUPPORT In Vitro

"The reason for this more pronounced defect in complex IV is not clear."

The authors explicitly state that this mechanistic question is unresolved.

Can the yeast MrpL3/mL44 homolog or a mouse Mrpl44 knockout serve as a valid model for human MRPL44 disease alleles, given that the human disease mutation modelled at the equivalent yeast residue does not impair function and that mouse null loss is embryonically lethal?

HUMAN MODEL MISMATCH OPEN mismatch_yeast_mrpl3_l156r_equivalent

Attached to

pathophysiology#Biallelic MRPL44 Loss of Function and mL44 Protein Depletion pathophysiology#Large Mitoribosomal Subunit Assembly Defect

Yeast MrpL3/mL44 is the tractable genetic model for mL44 function, and mutagenesis of its conserved hydrophobic pocket does identify residues critical for assembling translationally active mitoribosomes. However, the exact human disease substitution modelled at the equivalent yeast residue (A186) had no major functional impact, and the authors concluded the two orthologs have diverged in evolution. Mouse Mrpl44 loss is a different kind of mismatch: knockout is embryonically lethal, whereas human patients carry hypomorphic alleles with residual protein and survive with tissue-restricted disease. Neither model therefore reproduces the human hypomorphic, cardiac-selective genotype-phenotype relationship, and both should be treated as tools for general mitoribosome biology rather than as MRPL44 disease models. Patient-derived iPSC cardiomyocytes are the emerging replacement, but the only published line covers a single genotype and the work remains a preprint.

Proposed experiments

Isogenic MRPL44 iPSC-derived cardiomyocyte allelic series

isogenic iPSC-derived cardiomyocyte allelic series

exp_mrpl44_isogenic_ipsc_cardiomyocyte

Engineer an allelic series (p.Leu156Arg, p.Leu156Pro, p.Thr161Serfs*2, and corrected wild type) in a common human iPSC background, differentiate to cardiomyocytes, and quantify mL44 abundance, 39S assembly, mitochondrial translation, complex I and IV activity, and contractile function, testing whether the human cardiac context reproduces the allele-severity gradient that neither yeast nor mouse captures.

Model systems

Human iPSC-derived cardiomyocyte

Cardiomyocytes differentiated from gene-edited human iPSCs carrying the reported MRPL44 disease alleles, preserving the human sequence context that diverges from yeast MrpL3.

OTHER

Show evidence (3 references)

PMID:38950860 SUPPORT Model Organism

"the introduction of the disease-related mutation into the equivalent position in the yeast protein (residue A186) was found to not have a major impact on function"

Directly demonstrates that the yeast ortholog does not phenocopy the human disease allele.

PMID:38950860 SUPPORT Model Organism

"The human and yeast mL44 proteins share many similarities in sequence and structure; however results presented here indicate that these two proteins have diverged somewhat in evolution."

The authors themselves flag the evolutionary divergence limiting model validity.

PMID:34140213 SUPPORT Model Organism

"In mice, it is expressed widely throughout multiple tissues during development and its absence is embryonically lethal"

Mouse null lethality contrasts with the survivable, tissue-restricted human hypomorphic phenotype, the second arm of the model mismatch.

What determines the striking tissue gradient of MRPL44 deficiency, in which heart muscle shows profound respiratory chain deficiency, skeletal muscle intermediate, and fibroblasts only borderline changes, despite comparable reduction of mL44 protein in all three tissues?

KNOWLEDGE GAP OPEN gap_cardiac_tissue_selectivity

Attached to

pathophysiology#Cardiomyocyte Bioenergetic Failure and Mitochondrial Proliferation

mL44 protein levels are reduced in heart, skeletal muscle, and fibroblasts alike, yet the enzymatic and clinical consequences are overwhelmingly cardiac. Candidate explanations include the higher OXPHOS flux demand and mitochondrial density of the myocardium, the postnatal switch to fatty-acid oxidation (the nutrient-dependent hypothesis), tissue-specific differences in mitoribosome assembly-factor buffering, and a possible transcript hierarchy in mitochondrial translation - the yeast work showed that MrpL3/mL44 mutation does not affect all mtDNA-encoded transcripts equally. Distinguishing a threshold effect from a genuinely cardiac-specific mechanism is required before extrapolating any therapy tested in fibroblasts to the heart.

Show evidence (2 references)

PMID:34140213 SUPPORT Human Clinical

"There are tissue specific differences. The enzyme deficiency was most pronounced in cardiac muscle tissue, where there was massive proliferation of mitochondria on electron microscopy displacing contractile elements."

Documents the tissue gradient that this gap seeks to explain.

PMID:38950860 PARTIAL Model Organism

"we observed that mutation of the MrpL3/mL44 does not impact the translation of all mitochondrial encoded proteins equally, suggesting the mitochondrial translation system may exhibit a transcript hierarchy and prioritization."

Offers a candidate mechanism (transcript hierarchy) for differential consequences, though demonstrated in yeast rather than human tissue.

Does the postnatal glucose-to-fatty-acid fuel switch causally trigger MRPL44 hypertrophic cardiomyopathy in vivo, and does the ISRmt/lipid-handling arm represent a tractable therapeutic target distinct from OXPHOS repletion?

KNOWLEDGE GAP OPEN gap_nutrient_dependent_hypothesis_validation

Attached to

pathophysiology#Nutrient-Dependent Metabolic Stress Response in Cardiomyocytes

The nutrient-dependent model is currently supported by a single unreviewed preprint using one patient iPSC line in short-term culture, with immature in-vitro cardiomyocyte physiology. It is mechanistically attractive because it would explain the otherwise puzzling perinatal timing of disease onset, and because it points to a stress-signalling rather than purely bioenergetic target. It must not, however, be translated into fat restriction, ketogenic diet, or any other dietary manipulation: no clinical evidence supports this, and fasting/catabolic stress is itself a recognized hazard in mitochondrial disease. Replication across genotypes, in matured or engineered heart tissue, and ideally in vivo is required.

Proposed experiments

Multi-genotype nutrient-switch replication in matured cardiac tissue

engineered heart tissue nutrient-switch assay

exp_mrpl44_fuel_switch_replication

Replicate the glucose-versus-lipid comparison across at least three MRPL44 genotypes plus isogenic controls in maturation-promoted engineered heart tissue, with longitudinal transcriptomics, lipidomics, contractile force, and ISRmt readouts, and test whether pharmacological ISRmt attenuation rescues the lipid-condition phenotype.

Model systems

Engineered human heart tissue

Maturation-promoted 3D engineered heart tissue from MRPL44-mutant and isogenic control iPSCs, addressing the immaturity limitation of monolayer iPSC cardiomyocytes.

OTHER

Show evidence (1 reference)

DOI:10.1101/2025.09.24.678132 SUPPORT In Vitro

"Our findings indicate that glucose and lipids, the latter being the postnatally favored cardiac fuel, exert remarkably different consequences in MRPL44 deficient cardiomyocytes."

States the finding whose in-vivo validity and therapeutic tractability are the open question. Preprint, single patient line.

⚙

Pathophysiology

9

Biallelic MRPL44 Loss of Function and mL44 Protein Depletion

Biallelic pathogenic MRPL44 variants - most often the recurrent missense c.467T>G, p.(Leu156Arg) - destabilize the mL44 protein rather than abolishing its transcription, so patient heart, skeletal muscle, and fibroblasts all show sharply reduced steady-state mL44 levels. Frameshift alleles (e.g. c.481_484delinsTC, p.Thr161Serfs*2) are predicted to yield no protein at all, and a second substitution at the same residue, p.(Leu156Pro), is likewise strongly destabilizing. mL44 is a eukaryote-specific component of the large mitoribosomal subunit, forms a dimer, localizes to the mitochondrial matrix, and sits near the peptide exit channel.

MRPL44 hgnc:16650

mitochondrial large ribosomal subunit GO:0005762

Downstream

Large Mitoribosomal Subunit Assembly Defect Depletion of mL44 removes a structural component of the 39S subunit and compromises its assembly and stability.

Show evidence (3 references)

PMID:23315540 SUPPORT Human Clinical

"We found severely reduced MRPL44 levels in the patient's heart, skeletal muscle and fibroblasts suggesting that the missense mutation affected the protein stability."

Shows that the disease mechanism of the recurrent missense allele is loss of mL44 protein stability across all tissues examined.

PMID:26221731 SUPPORT In Vitro

"We found that it can form multimers, and confirm that it is part of the large subunit of the mitochondrial ribosome."

Confirms mL44 is a bona fide constituent of the large mitoribosomal subunit that oligomerizes.

PMID:26221731 SUPPORT In Vitro

"we show by immunofluorescence microscopy and subcellular fractionation that Mrpl44 is localized to the matrix of the mitochondria."

Establishes the mitochondrial matrix localization of mL44.

Large Mitoribosomal Subunit Assembly Defect

Loss of mL44 reduces the amount of assembled large (39S) mitoribosomal subunit and destabilizes the mtDNA-encoded 16S rRNA that forms its scaffold, while leaving the small (28S) subunit largely intact. Retroviral re-expression of wild-type MRPL44 in patient fibroblasts restores the large subunit assembly defect, establishing the causal direction.

mitochondrial large ribosomal subunit assembly GO:1902775 ↓ DECREASED

mitochondrial large ribosomal subunit GO:0005762

Downstream

Impaired Mitochondrial Translation Fewer translationally competent mitoribosomes reduce the rate of synthesis of mtDNA-encoded polypeptides.

Show evidence (3 references)

PMID:23315540 SUPPORT In Vitro

"In patient fibroblasts, decreased MRPL44 affected assembly of the large ribosomal subunit and stability of 16S rRNA leading to complex IV deficiency."

Directly demonstrates the 39S assembly and 16S rRNA stability defect in patient cells.

PMID:23315540 SUPPORT In Vitro

"Retroviral expression of wild-type MRPL44 in patient fibroblasts rescued the large ribosome assembly defect and COX deficiency."

Genetic complementation establishes that MRPL44 loss is causal for the assembly and cytochrome c oxidase defects.

PMID:33742325 SUPPORT In Vitro

"These studies confirmed that c.467 T > G affects the stability or assembly of the large subunit of the mitochondrial ribosome, leading to impaired mitochondrial protein synthesis and decreased levels of multiple OXPHOS components."

Independent replication in a second laboratory of the 39S assembly defect caused by the recurrent allele.

Impaired Mitochondrial Translation

The assembly defect lowers mitochondrial protein synthesis, measured by 35S-amino-acid incorporation into mtDNA-encoded polypeptides in patient fibroblasts. The reduction affects all thirteen mtDNA-encoded subunits rather than a single complex, and its magnitude tracks the severity of the underlying genotype - a null/missense compound heterozygote had roughly a third of control incorporation, while a missense/missense compound heterozygote retained more. mL44 sits at the peptide exit tunnel, and the original report noted the assembly defect exceeded the de novo translation defect in fibroblasts, suggesting an additional role in the folding or stability of nascent polypeptides as they leave the ribosome.

Postnatal glucose-to-fatty-acid fuel switch as the trigger for MRPL44 cardiomyopathy manifestation

fibroblast CL:0000057

mitochondrial translation GO:0032543 ↓ DECREASED

Downstream

Failed Compensatory mtDNA Replication and Transcription Cardiomyocytes respond to the translation block by amplifying mtDNA and mitochondrial transcripts, a response that cannot restore protein output. Hypothesis-tagged: rests on a single unreviewed patient iPSC-cardiomyocyte study, and a mouse NIH3T3 knockdown study found no mtDNA copy-number effect.

Combined Complex I and IV Deficiency Reduced supply of mtDNA-encoded subunits prevents assembly of the respiratory chain complexes that contain them.

Show evidence (3 references)

PMID:34140213 SUPPORT In Vitro

"We show this to be caused by reduced mitochondrial DNA encoded protein synthesis affecting all subunits, and resulting in dysfunction of complex I and IV assembly."

Establishes globally reduced mtDNA-encoded protein synthesis as the proximate cause of the OXPHOS assembly defects.

PMID:34140213 SUPPORT In Vitro

"The degree of oxidative phosphorylation dysfunction correlated with the impairment of mitochondrial protein synthesis due to different pathogenic variants."

Demonstrates a genotype-to-translation-to-OXPHOS dose relationship across alleles.

PMID:23315540 PARTIAL In Vitro

"Despite this assembly defect, de novo mitochondrial translation was only mildly affected in fibroblasts suggesting that MRPL44 may have a function in the assembly/stability of nascent mitochondrial polypeptides exiting the ribosome."

Qualifies the translation defect - in fibroblasts of the index family the de novo translation deficit was mild, raising an additional peptide-exit chaperoning role for mL44.

Failed Compensatory mtDNA Replication and Transcription

In MRPL44-mutant patient iPSC-derived cardiomyocytes grown in glucose-rich (fetal-like) medium, mtDNA copy number rises about 2.5-fold and mtDNA-encoded transcripts - particularly complex I and complex V subunits - are strongly induced, with increased mitochondrial content per cell. Despite this transcriptional and replicative upregulation, steady-state complex I protein remains markedly reduced: the cell mounts a mitochondrial biogenesis response that operates upstream of, and therefore cannot bypass, the translation block. This is the cellular counterpart of the mitochondrial proliferation seen ultrastructurally in patient myocardium.

Postnatal glucose-to-fatty-acid fuel switch as the trigger for MRPL44 cardiomyopathy manifestation

cardiac muscle cell CL:0000746

mitochondrial DNA replication GO:0006264 ↑ INCREASED mitochondrial transcription GO:0006390 ↑ INCREASED

Downstream

Nutrient-Dependent Metabolic Stress Response in Cardiomyocytes Compensation that suffices under fetal glucose-based fuel fails when the postnatal heart switches to fatty-acid oxidation.

Show evidence (3 references)

DOI:10.1101/2025.09.24.678132 SUPPORT In Vitro

"The patient CMs showed an increase of 2.5-fold in mtDNA copy number compared to controls"

Quantifies the compensatory mtDNA amplification in patient cardiomyocytes. Preprint evidence from a single patient iPSC line.

DOI:10.1101/2025.09.24.678132 SUPPORT In Vitro

"Despite this transcriptional upregulation, steady-state complex I protein level was markedly reduced"

Shows the compensatory response fails to restore OXPHOS subunit protein. Preprint evidence.

PMID:26221731 PARTIAL In Vitro

"Thus, Mrpl44 appears to regulate mitochondrial genome expression rather than copy number."

Counterpoint - in mouse NIH3T3 cells, altering Mrpl44 expression changed mitochondrial gene expression but NOT mtDNA copy number. Scored PARTIAL rather than REFUTE because the systems differ (rodent knockdown/ overexpression versus a human p.Leu156Arg iPSC-cardiomyocyte), but it means the compensatory mtDNA amplification is not yet an established feature of MRPL44 deficiency.

Nutrient-Dependent Metabolic Stress Response in Cardiomyocytes

Under lipid-enriched (postnatal-like) conditions, MRPL44-mutant iPSC cardiomyocytes activate the mitochondrial integrated stress response (ISRmt) - ATF5 with its targets TRIB3, ASNS, MTHFD2 and GDF15, plus DDIT3, the de novo serine biosynthesis genes PSAT1/PSPH and CEBPG - alongside partial ER stress (HERPUD1, NUPR1, XBP1, CHAC1, HSPA5, without XBP1 splicing). FGF21 induction is notably absent. The cells simultaneously accumulate lipid droplets and upregulate lipid-uptake and cholesterol-synthesis genes, a maladaptive rewiring that the authors link to persistent anabolic signaling rather than to ATP deficiency alone. This node is hypothesis-tagged: the evidence is preprint, in vitro, and from one patient genotype.

Postnatal glucose-to-fatty-acid fuel switch as the trigger for MRPL44 cardiomyopathy manifestation

cardiac muscle cell CL:0000746

fatty acid beta-oxidation GO:0006635 ↓ DECREASED

Downstream

Cardiomyocyte Bioenergetic Failure and Mitochondrial Proliferation Proposed route by which nutrient-conditional stress signaling, not ATP deficit alone, drives pathological hypertrophic growth.

Show evidence (3 references)

DOI:10.1101/2025.09.24.678132 SUPPORT In Vitro

"In contrast the lipid-enriched medium triggered both mitochondrial and endoplasmic reticulum -related stress responses, disrupted lipid and cholesterol homeostasis, accompanied by remodeling of the central biosynthetic pathway of one carbon metabolism."

Documents the nutrient-conditional stress response. Preprint, in vitro, single patient line.

DOI:10.1101/2025.09.24.678132 SUPPORT In Vitro

"The cells accumulated lipids while also inducing lipid uptake and synthesis genes, suggesting maladaptive metabolic rewiring."

Documents the maladaptive lipid handling in mutant cardiomyocytes.

DOI:10.1101/2025.09.24.678132 SUPPORT In Vitro

"Mitochondrial ribosome defect disrupts lipid homeostasis in cardiomyocytes causing impaired fatty acid oxidation, lipid accumulation and altered cholesterol metabolism."

Directly supports the decreased fatty acid beta-oxidation annotation on this node. Preprint, in vitro, single patient line.

Combined Complex I and IV Deficiency

Because only complexes I, III, IV, and V contain mtDNA-encoded subunits, the translation defect produces a combined rather than isolated respiratory chain deficiency, with a reproducible emphasis on complex IV and complex I. Blue-native PAGE shows incompletely assembled complex I and reduced complex IV holocomplex, MT-CO1 protein is reduced while the nuclear-encoded ATP5F1B is normal, and high-resolution respirometry shows deficient complex I- and complex IV-linked oxygen consumption. The disproportionate complex IV involvement is unexplained, since the measured synthesis rates of complex I and complex IV subunits are similarly reduced.

mitochondrial respiratory chain complex I assembly GO:0032981 ↓ DECREASED mitochondrial respiratory chain complex IV assembly GO:0033617 ↓ DECREASED oxidative phosphorylation GO:0006119 ↓ DECREASED

Downstream

Cardiomyocyte Bioenergetic Failure and Mitochondrial Proliferation The energy-demanding myocardium is the tissue least able to tolerate the OXPHOS deficit.

Systemic Energy Deficit and Late Multisystem Involvement Lower-threshold tissues decompensate only after prolonged exposure to the partial OXPHOS deficit, giving a second- and third-decade multisystem phenotype.

Show evidence (3 references)

PMID:23315540 SUPPORT Human Clinical

"Analysis of respiratory chain enzymes revealed a combined deficiency of complexes I and IV in the heart and skeletal muscle."

The defining biochemical signature of MRPL44 deficiency in patient tissue.

PMID:34140213 SUPPORT Human Clinical

"We document a combined respiratory chain enzyme deficiency with emphasis on complex I and IV, affecting heart muscle tissue more than skeletal muscle or fibroblasts."

Replicates the combined CI/CIV deficiency and establishes its tissue gradient.

PMID:26221731 SUPPORT In Vitro

"This ultimately impacted ATP synthesis capability and respiratory capacity of cells."

Independent experimental manipulation of Mrpl44 expression reproduces the OXPHOS capacity defect.

Cardiomyocyte Bioenergetic Failure and Mitochondrial Proliferation

Cardiac muscle shows the most profound enzyme deficiency of any tissue examined, with a profound decrease in complex IV, a strong decrease in complex I, and incompletely assembled complex V. Electron microscopy of the myocardium shows a diffuse proliferation of enlarged, atypically shaped mitochondria with aberrant cristae that displace and replace contractile elements - the structural correlate of compensatory mitochondrial biogenesis failing to restore ATP supply. The result is hypertrophic remodelling and progressive contractile failure of the neonatal and infant heart.

cardiac muscle cell CL:0000746

heart UBERON:0000948

Downstream

Progressive Heart Failure Loss of contractile mass and hypertrophic remodelling reduce cardiac output.

Show evidence (2 references)

PMID:34140213 SUPPORT Human Clinical

"The enzyme deficiency was most pronounced in cardiac muscle tissue, where there was massive proliferation of mitochondria on electron microscopy displacing contractile elements."

Links the tissue-graded biochemical defect to the cardiac structural pathology.

PMID:23315540 SUPPORT Human Clinical

"These findings indicate that mitochondrial ribosomal subunit defects can generate tissue-specific manifestations, such as cardiomyopathy."

Frames the cardiac-selective manifestation as the central conceptual finding of MRPL44 deficiency.

Progressive Heart Failure

Hypertrophic cardiomyopathy in MRPL44 deficiency progresses to overt ventricular dysfunction, cardiomegaly, and in the most severe infantile cases cardiogenic shock with secondary hepatic and renal failure requiring inotropes, ventricular assist devices, and extracorporeal membrane oxygenation. Some infants stabilize after the first year and remain asymptomatic into adolescence.

heart UBERON:0000948

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"she was readmitted in cardiogenic shock, hypotensive, hypoglycemic, lethargic and hypoxic, likely due to right ventricular failure."

Documents progression from compensated hypertrophic cardiomyopathy to cardiogenic shock with right ventricular failure. (The same report records that this infant subsequently died; the fatal outcome is cited separately under the mechanical circulatory support treatment.)

Systemic Energy Deficit and Late Multisystem Involvement

Outside the heart the same combined OXPHOS deficiency produces a lower-grade, cumulative energy deficit. In skeletal muscle it manifests as exercise intolerance, easy fatigue, and myopathy; in liver as steatosis with elevated transaminases; in kidney as renal insufficiency; and in the central nervous system and retina - typically only in the second and third decades - as hemiplegic migraine, transient hemiparesis and confusion, spasticity, ataxia, pigmentary retinopathy, and Leigh-like lesions of the thalami, basal ganglia, midbrain and cerebellum.

oxidative phosphorylation GO:0006119 ↓ DECREASED

Show evidence (2 references)

PMID:25797485 SUPPORT Human Clinical

"However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."

Enumerates the late multisystem features of MRPL44 deficiency.

PMID:33742325 SUPPORT Human Clinical

"confirms that MRLP44 mutations cause a mitochondrial translation defect that may present as a multisystem disorder with neurological involvement."

Independent confirmation that the translation defect can present as multisystem disease with neurological involvement.

✶

Histopathology

2

Mitochondrial Proliferation with Aberrant Cristae in Cardiomyocytes

Electron microscopy of myocardial biopsy shows a diffuse proliferation of enlarged, atypically shaped mitochondria with aberrant cristae together with areas of contractile element loss - the classic ultrastructural picture of a mitochondrial cardiomyopathy.

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"In Patient 1, on electron microscopy, the heart showed areas of contractile element loss within the cardiomyocytes and a diffuse proliferation of enlarged, atypically shaped mitochondria with aberrant cristae, typical for a mitochondrial cardiomyopathy"

Direct ultrastructural description of the cardiac histopathology.

Abnormal Skeletal Muscle Mitochondria without Ragged Red Fibers

Skeletal muscle shows abnormal mitochondria with granular content and abnormal cristae, and enlarged mitochondria in some fibers. Notably, Gomori trichrome staining did not reveal ragged blue fibers and there were no cytochrome c oxidase-negative fibers, so routine mitochondrial muscle histochemistry can be unrevealing in MRPL44 deficiency.

Show evidence (2 references)

PMID:34140213 SUPPORT Human Clinical

"In Patient 2, on light microscopy skeletal muscle showed abnormal mitochondria with granular content and abnormal cristae, and in some fibers enlarged mitochondria were noted."

Describes the skeletal muscle mitochondrial abnormalities.

PMID:34140213 SUPPORT Human Clinical

"Gomori trichrome staining did not reveal ragged blue fibers, and there were no cytochrome c oxidase negative fibers."

Establishes that the standard mitochondrial myopathy histochemical markers may be absent, an important diagnostic caveat.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

17

Cardiovascular 3

Hypertrophic Cardiomyopathy VERY_FREQUENT Hypertrophic cardiomyopathy HP:0001639

Course: PROGRESSIVE

Show evidence (2 references)

PMID:25797485 SUPPORT Human Clinical

"Both patients presented with childhood-onset hypertrophic cardiomyopathy, which seems to be the core clinical feature associated with MRPL44 deficiency."

Explicitly identifies hypertrophic cardiomyopathy as the core feature, supporting a VERY_FREQUENT frequency band.

PMID:34140213 SUPPORT Human Clinical

"All patients presented as children with hypertrophic cardiomyopathy, had mild lactic acidosis, and easy fatigue and muscle weakness."

Confirms hypertrophic cardiomyopathy in all five previously published patients (5/5). The literature term "all" would map to OBLIGATE, but VERY_FREQUENT is used deliberately as the conservative band because the denominator is a nine-patient literature total, not a systematically ascertained cohort.

Left Ventricular Hypertrophy Left ventricular hypertrophy HP:0001712

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"an echocardiogram revealed an ejection fraction of 25% (normal 55–70%) with left ventricular dysfunction and hypertrophy"

Documents echocardiographic left ventricular dysfunction and hypertrophy in an affected infant.

Congestive Heart Failure Congestive heart failure HP:0001635

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"She had cardiomegaly on chest X-ray, and echocardiography showed a very restrictive right ventricle and a ballooned left ventricle with barely any unmeasurable contraction and blood flow, and she died in cardiac failure shortly after."

Documents fatal congestive cardiac failure in an infant with MRPL44 deficiency.

Digestive 1

Hepatic Steatosis Hepatic steatosis HP:0001397

Show evidence (2 references)

ORPHA:352563 SUPPORT Other

"A rare mitochondrial oxidative phosphorylation disorder with complex I and IV deficiency characterized by hypertrophic cardiomyopathy, hepatic steatosis with elevated liver transaminases, exercise intolerance and muscle weakness."

Orphanet's expert clinical definition includes hepatic steatosis with elevated liver transaminases as a characteristic feature.

PMID:25797485 PARTIAL Human Clinical

"However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."

The primary report documents hepatopathy but does not itself specify steatosis, so this is scored PARTIAL for the steatosis claim.

Eye 1

Pigmentary Retinopathy Pigmentary retinopathy HP:0000580

Show evidence (1 reference)

PMID:25797485 SUPPORT Human Clinical

"However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."

Reports pigmentary retinopathy among the late features observed in this two-patient series. No frequency band is assigned - the source gives no count or qualitative frequency term.

Genitourinary 1

Renal Insufficiency Renal insufficiency HP:0000083

Show evidence (1 reference)

PMID:25797485 SUPPORT Human Clinical

"However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."

Reports renal insufficiency among the additional features of the two patients in this series. No frequency band is assigned: the source enumerates features without per-patient attribution or any count, so any band would be unsupported.

Metabolism 3

Lactic Acidosis FREQUENT Lactic acidosis HP:0003128

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"Three presented as infants with hypertrophic cardiomyopathy, mild lactic acidosis, and easy fatigue and muscle weakness, whereas two presented in adolescence with myopathy and neurological symptoms."

Documents lactic acidosis in three of the five previously reported patients plus one of the two new infants (4/7 = 57%), a derived count supporting the FREQUENT band (30-79%). Note the same paper's body text states that "All patients ... had mild lactic acidosis", conflicting with its own abstract; the lower abstract count is used as the conservative basis.

Hypoglycemia Hypoglycemia HP:0001943

Temporal: RECURRENT

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"We describe two infants who presented with cardiomyopathy from the neonatal period, failure to thrive, hypoglycemia and in one infant lactic acidosis."

Documents hypoglycemia as part of the infantile presentation.

Elevated Hepatic Transaminases Elevated circulating hepatic transaminase concentration HP:0002910

Show evidence (1 reference)

ORPHA:352563 SUPPORT Other

"hepatic steatosis with elevated liver transaminases"

Orphanet clinical definition lists elevated liver transaminases.

Musculoskeletal 3

Muscle Weakness VERY_FREQUENT Muscle weakness HP:0001324

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"All patients presented as children with hypertrophic cardiomyopathy, had mild lactic acidosis, and easy fatigue and muscle weakness."

Reports easy fatigue and muscle weakness in all five previously published patients (5/5). Mapped to VERY_FREQUENT (80-100%) rather than OBLIGATE because the two infants added by this 2021 report were not separately scored for weakness.

Myopathy Myopathy HP:0003198

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"Three presented as infants with hypertrophic cardiomyopathy, mild lactic acidosis, and easy fatigue and muscle weakness, whereas two presented in adolescence with myopathy and neurological symptoms."

Documents myopathy as the presenting feature of the two later-onset patients, distinguishing the adolescent/adult phenotype from the infantile cardiac-dominant one.

Spasticity Spasticity HP:0001257

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"transient episodes of neurological dysfunction of hemiparesis and confusion, spasticity and ataxia, and on brain MRI lesions in basal ganglia, thalami and midbrain and subcortical and cerebellar white matter"

Documents spasticity in the adult multisystem presentation.

Nervous System 2

Hemiplegic Migraine Migraine HP:0002076

Show evidence (1 reference)

PMID:25797485 SUPPORT Human Clinical

"However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."

Documents hemiplegic migraine as a late feature in this two-patient series. No frequency band is assigned - the source gives no count. HPO has no dedicated hemiplegic migraine term, so the generic Migraine term is used with a more specific preferred_term.

Ataxia Ataxia HP:0001251

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"transient episodes of neurological dysfunction of hemiparesis and confusion, spasticity and ataxia, and on brain MRI lesions in basal ganglia, thalami and midbrain and subcortical and cerebellar white matter"

Documents ataxia in a single adult patient. Per the frequency guidelines a single case maps to "omit frequency", so no band is assigned.

Constitutional 1

Exercise Intolerance Exercise intolerance HP:0003546

Show evidence (2 references)

ORPHA:352563 SUPPORT Other

"hypertrophic cardiomyopathy, hepatic steatosis with elevated liver transaminases, exercise intolerance and muscle weakness"

The Orphanet clinical definition of COXPD16 lists exercise intolerance as a characteristic feature.

PMID:34140213 SUPPORT Human Clinical

"A fifth patient presented as a young adult with skeletal myopathy and exercise intolerance, subclinical cardiac hypertrophy recognized at age 21 years"

Documents exercise intolerance as a presenting adult feature.

Growth 1

Failure to Thrive Failure to thrive HP:0001508

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"We describe two infants who presented with cardiomyopathy from the neonatal period, failure to thrive, hypoglycemia and in one infant lactic acidosis."

Documents failure to thrive in the infantile presentation.

Other 1

Learning Difficulties Specific learning disability HP:0001328

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"The fourth patient from age 14 years on developed cardiomyopathy, hemiplegic migraines, learning difficulties, myopathy, tapetoretinal dystrophy, and Leigh-like lesions in thalami, basal ganglia and cerebellum on brain MRI"

Documents learning difficulties in a single adolescent-onset patient.

🧬

Genetic Associations

1

MRPL44 biallelic pathogenic variants

Gene: MRPL44 hgnc:16650 relationship_type: CAUSATIVE variant_origin: GERMLINE

Autosomal recessive

Show evidence (1 reference)

PMID:30384889 SUPPORT Human Clinical

"The disease genes converge on metabolic causes (PRKAG2, MRPL44, AARS2, HADHB, DNAJC19, PPA2, TAZ, BAG3), MAPK pathways (HRAS, PTPN11, RAF1, TAB2), development (NEK8 and TBX20), calcium signaling (JPH2, CALM1, CACNA1C), and the sarcomeric contraction cycle (TNNC1, TNNI3, ACTC1, MYH7, NRAP)."

A countrywide severe childhood cardiomyopathy cohort places MRPL44 among the established metabolic cardiomyopathy genes.

💊

Medical Actions

6

Supportive Heart Failure Management

Action: supportive care Ontology label: Supportive Care NCIT:C15747

No disease-modifying therapy exists. Care is supportive and cardiac-directed: beta blockade and standard anti-failure pharmacotherapy, nutritional support via nasogastric or gastrostomy feeding, avoidance of catabolic stress, and surveillance echocardiography. Intercurrent infection is a recognized trigger of fatal cardiac decompensation.

Target Phenotypes: Congestive heart failure HP:0001635

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"The patient responded well to treatment and was discharged at 71 days of life while being treated with beta blockers and receiving feeding mainly via gastrostomy tube."

Documents beta blockade and enteral nutritional support as the initial management, with initial clinical response.

Beta Blocker Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: beta-adrenergic antagonist NCIT:C29576

Beta blockade is the specific anti-failure pharmacotherapy documented in MRPL44 deficiency; an affected infant was discharged on beta blockers with gastrostomy feeding after an initial clinical response, although the cardiomyopathy later decompensated fatally.

Target Phenotypes: Congestive heart failure HP:0001635

Show evidence (1 reference)

PMID:34140213 PARTIAL Human Clinical

"The patient responded well to treatment and was discharged at 71 days of life while being treated with beta blockers and receiving feeding mainly via gastrostomy tube."

Documents beta blockade in an affected infant with an initial response. Scored PARTIAL - this is single-case, uncontrolled use extrapolated from general pediatric heart failure practice, not MRPL44-specific efficacy data.

Genetic Counseling

Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Autosomal recessive counselling with a specific caveat: one reported patient was homozygous through complete maternal uniparental isodisomy of chromosome 2 rather than biparental transmission. A homozygous MRPL44 result with only one carrier parent should therefore prompt uniparental disomy testing, since the recurrence risk differs substantially from the standard 25%.

Show evidence (1 reference)

PMID:33742325 SUPPORT Human Clinical

"Short-tandem repeat and genome-wide SNP microarray analyses of the family trio confirmed complete maternal uniparental isodisomy of chromosome 2."

Establishes uniparental isodisomy as a documented route to homozygosity in MRPL44 disease, which directly changes recurrence-risk counselling.

Mechanical Circulatory Support

Action: ventricular assist device placement Ontology label: Ventricular Assist Device Placement NCIT:C80452

Ventricular assist device placement and venoarterial extracorporeal membrane oxygenation have been used aggressively in infants with MRPL44-related cardiogenic shock, on the rationale that some patients stabilize after the first year. In the published case this did not prevent death from multiorgan failure and opportunistic infection, so the benefit is unproven.

Mechanism Target:

INHIBITS Progressive Heart Failure — Mechanical unloading substitutes for the failing bioenergetically depleted myocardium; it does not correct the underlying translation defect.

Show evidence (2 references)

PMID:34140213 SUPPORT Human Clinical

"aggressive management including left ventricle assist device was performed in the case presented here."

Documents the use of mechanical circulatory support and its rationale.

PMID:34140213 PARTIAL Human Clinical

"She remained in cardiogenic shock and hepatic failure, and ultimately developed disseminated Candida lusitanease infection which resulted in her death two days after her first birthday."

Shows that mechanical support did not rescue the reported infant, so efficacy is unestablished.

Cardiac Transplantation

Action: heart transplantation Ontology label: Heart Transplantation NCIT:C15246

Cardiac transplantation has been explicitly considered for infantile MRPL44-related cardiomyopathy, since the heart bears the most severe biochemical defect. The counterargument, which must be discussed at the time of listing, is that the same OXPHOS deficiency persists in all other tissues and can produce progressive neurological, ophthalmological, renal, and hepatic disease in the second and third decades.

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"We were considering cardiac transplantation as an option in this condition in infancy, bearing in mind that in adolescence a progressive clinical involvement including neurological symptoms may still occur."

States both the rationale for and the principal caveat against cardiac transplantation in MRPL44 deficiency.

Mitochondrial Biogenesis Induction (Investigational)

Action: investigational pharmacotherapy Ontology label: Pharmacotherapy NCIT:C15986

Because disease severity tracks residual mL44 abundance rather than complete absence of the protein, pharmacological upregulation of MRPL44 expression has been proposed as a rational therapeutic strategy - specifically mitochondrial biogenesis inducers such as NRF2, PGC-1-alpha, or PPAR-delta activators. This is a hypothesis only: no preclinical or clinical data exist in MRPL44 deficiency, and patient cardiomyocytes already show a spontaneous but ineffective mitochondrial biogenesis response, which tempers the rationale.

Mechanism Target:

INHIBITS Biallelic MRPL44 Loss of Function and mL44 Protein Depletion — Raising MRPL44 transcription is proposed to partially compensate for the reduced steady-state abundance of the destabilized mL44 protein.

Show evidence (2 references)

PMID:34140213 PARTIAL Human Clinical

"Since the amount of residual activity is related to translational efficiency, to improve the function and perhaps allow infants to recover from the cardiac dysfunction, increasing the amount of ml44 should be considered."

States the therapeutic hypothesis. Scored PARTIAL because the paper proposes but does not test this strategy.

DOI:10.1101/2025.09.24.678132 PARTIAL In Vitro

"MRPL44 deficiency impairs mitochondrial translation but induces mtDNA replication and transcription in iPSC-derived cardiomyocytes."

Tempers the biogenesis-induction rationale - patient cardiomyocytes already mount a biogenesis response that fails to correct the translation block. Preprint, in vitro.

🔬

Biochemical Markers

5

Increased circulating lactate concentration (INCREASED)

Context: Elevated blood lactate, generally mild but occasionally severe. One neonate had persistent lactic acidemia of 3.3 to 15 mmol/L unrelated to feeding, with an elevated lactate/pyruvate ratio indicating a respiratory chain rather than a pyruvate dehydrogenase defect.

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"The persistent lactic acidemia (3.3 to 15 mmol/L, normal < 2 mM) did not change in relation to feeding"

Quantifies the persistent elevation of blood lactate.

Reduced cytochrome c oxidase (complex IV) enzyme activity (DECREASED)

Context: The most consistently and most severely reduced respiratory chain activity. In cardiac tissue complex IV activity is profoundly decreased; in skeletal muscle it is severely to mildly decreased; in fibroblasts it is only borderline low, and may only be detectable in a mitochondrial isolate rather than a whole-cell homogenate.

Show evidence (2 references)

PMID:34140213 SUPPORT Human Clinical

"in Patient 1 respiratory chain enzyme activities showed a combined deficiency of the activities of respiratory chain enzyme complexes in heart tissue, with a profound decrease in complex IV and a strong decrease in complex I, and a mild decrease of complex II-III"

Quantifies the tissue-specific respiratory chain enzyme deficiencies.

PMID:34140213 SUPPORT In Vitro

"In fibroblasts the respiratory chain enzyme activities were normal in the 600 × g homogenate, but showed low complex IV activity in a mitochondrial isolate."

Important diagnostic caveat - fibroblast whole-homogenate assays can miss the complex IV defect.

Reduced NADH:ubiquinone oxidoreductase (complex I) enzyme activity (DECREASED)

Context: Complex I activity is strongly reduced in cardiac tissue and mildly to moderately reduced in skeletal muscle, completing the combined complex I and IV deficiency signature.

Show evidence (1 reference)

PMID:23315540 SUPPORT Human Clinical

"Analysis of respiratory chain enzymes revealed a combined deficiency of complexes I and IV in the heart and skeletal muscle."

Documents combined complex I and IV deficiency in patient heart and muscle.

Reduced mitochondrial protein synthesis in fibroblasts (DECREASED)

Context: Quantitative 35S-amino-acid incorporation into mtDNA-encoded polypeptides is reduced to approximately one third of control values in fibroblasts from a patient with a missense/frameshift genotype, and to approximately half in a patient with a missense/missense genotype - a functional assay that both confirms the translation defect and grades allele severity.

Show evidence (2 references)

PMID:34140213 SUPPORT In Vitro

"clearly decreased synthesis of mitochondrial proteins at 2.23 ± 0.48 fmol AA/μg protein, 33% of the average incorporation (p<0.01)"

Quantifies the translation deficit in the missense/frameshift patient's fibroblasts at 33% of control incorporation.

PMID:34140213 SUPPORT In Vitro

"The degree of oxidative phosphorylation dysfunction correlated with the impairment of mitochondrial protein synthesis due to different pathogenic variants."

Establishes the quantitative translation assay as a genotype-severity readout.

Reduced MT-CO1 protein with preserved nuclear-encoded ATP5F1B (DECREASED)

Context: Western blotting shows reduced MT-CO1 (a mtDNA-encoded complex IV subunit) in all tissues examined while the nuclear-encoded ATP synthase subunit ATP5F1B is normal - a discriminating pattern that localizes the defect to mitochondrial rather than cytosolic translation.

Show evidence (1 reference)

PMID:34140213 SUPPORT In Vitro

"The amount of MT-CO1 was decreased in all tissues, but the amount of ATP5FB1 was normal"

Demonstrates selective loss of a mtDNA-encoded subunit with preservation of a nuclear-encoded one.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from MRPL44 Deficiency:

MRPL3-related combined oxidative phosphorylation deficiency (COXPD9) Not Yet Curated MONDO:0013811

Overlapping Features The closest mimic. MRPL3 encodes another protein of the same large (39S) mitoribosomal subunit, so COXPD9 shares the exact mechanism - a mitoribosomal translation defect - and presents with infantile-onset severe hypertrophic cardiomyopathy, failure to thrive, raised lactate, abnormal liver enzymes and a combined respiratory chain deficiency.

Distinguishing Features

Only molecular testing separates them reliably. COXPD9 characteristically involves complexes I, III, IV and V, whereas MRPL44 deficiency shows the complex I and IV emphasis; COXPD9 also features prominent psychomotor delay and hepatomegaly from infancy, while MRPL44 cognition is typically normal in infancy with neurological features deferred to the second and third decades.

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"Of these, cardiomyopathy has for instance been described in the following genes: AARS2, YARS2, GARS, KARS, MRPL3, MRPS22, MRPS14, MRPL44, TSFM, RMND1, MTO1, HSD17B10, ELAC2, TRMT5, GTPBP3 [3]."

Lists MRPL3 alongside MRPL44 among the mitochondrial translation genes causing cardiomyopathy.

MTO1 deficiency (mitochondrial hypertrophic cardiomyopathy with lactic acidosis) Not Yet Curated MONDO:0013865

Overlapping Features A mitochondrial tRNA-modification (rather than mitoribosomal structural) translation defect presenting with infantile hypertrophic cardiomyopathy and lactic acidosis. Clinically near-indistinguishable from MRPL44 deficiency at presentation, and a documented source of named-entity confusion in the literature and in automated curation.

Distinguishing Features

Molecular. MTO1 acts on mt-tRNA taurinomethyl modification, not on the 39S subunit; lactic acidosis is typically more severe and more consistently present in MTO1 deficiency, and MTO1 patients more often show early encephalopathy.

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"Of these, cardiomyopathy has for instance been described in the following genes: AARS2, YARS2, GARS, KARS, MRPL3, MRPS22, MRPS14, MRPL44, TSFM, RMND1, MTO1, HSD17B10, ELAC2, TRMT5, GTPBP3 [3]."

Lists MTO1 among the mitochondrial translation cardiomyopathy genes.

Other mitochondrial translation-defect cardiomyopathies

Overlapping Features A broader group of nuclear mitochondrial translation genes causes biochemically indistinguishable infantile cardiomyopathy with combined respiratory chain deficiency: aminoacyl-tRNA synthetases (AARS2, YARS2, GARS, KARS), other mitoribosomal proteins (MRPS22, MRPS14), elongation and assembly factors (TSFM, RMND1), and tRNA-modifying enzymes (ELAC2, TRMT5, GTPBP3, HSD17B10).

Distinguishing Features

Not separable on respiratory chain enzymology or muscle histology; requires a nuclear mitochondrial gene panel, exome, or genome. This is the practical argument for not stopping at a targeted cardiomyopathy panel.

Show evidence (1 reference)

PMID:34140213 SUPPORT Human Clinical

"Of these, cardiomyopathy has for instance been described in the following genes: AARS2, YARS2, GARS, KARS, MRPL3, MRPS22, MRPS14, MRPL44, TSFM, RMND1, MTO1, HSD17B10, ELAC2, TRMT5, GTPBP3 [3]."

Enumerates the mitochondrial translation genes in which cardiomyopathy has been described, defining this differential group.

SLC25A3-related cardiomyopathy-hypotonia-lactic acidosis syndrome MONDO:0012557

Overlapping Features Mitochondrial phosphate-carrier deficiency presenting with infantile hypertrophic cardiomyopathy, hypotonia, and lactic acidosis - overlapping the MRPL44 infantile presentation closely enough to be a recognized confusable entity.

Distinguishing Features

Mechanistically distinct: a solute-carrier (substrate import) defect rather than a translation defect, so mitochondrial protein synthesis and mitoribosome assembly are normal and the respiratory chain deficiency pattern differs. Marked hypotonia is a more prominent early feature.

Non-mitochondrial metabolic and sarcomeric infantile cardiomyopathies

Overlapping Features Pompe disease (glycogen storage disease II), Barth syndrome (TAZ), fatty-acid-oxidation defects, and primary sarcomeric hypertrophic cardiomyopathy all present with infantile or childhood hypertrophic cardiomyopathy.

Distinguishing Features

These are separable without sequencing: Pompe by acid alpha-glucosidase enzyme assay and marked creatine kinase elevation; Barth by cyclic 3-methylglutaconic aciduria, neutropenia and X-linked inheritance; fatty-acid-oxidation defects by a diagnostic acylcarnitine profile; sarcomeric HCM by dominant inheritance, later onset, and the absence of lactic acidosis or combined respiratory chain deficiency.

{ }

Source YAML

click to show

name: MRPL44 Deficiency
category: Genetic
creation_date: "2026-08-01T00:00:00Z"
synonyms:
- COXPD16
- Combined oxidative phosphorylation deficiency 16
- Combined oxidative phosphorylation defect type 16
- Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency
- MRPL44-related mitochondrial disease
description: >
  Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency (COXPD16;
  OMIM #615395; ORPHA:352563) is an ultra-rare autosomal recessive disorder of
  mitochondrial translation caused by biallelic pathogenic variants in MRPL44,
  which encodes mL44, a eukaryote-specific structural protein of the large (39S)
  subunit of the mitochondrial ribosome located near the peptide exit tunnel.
  Loss of mL44 destabilizes the large mitoribosomal subunit and 16S rRNA,
  reducing synthesis of the thirteen mtDNA-encoded respiratory chain subunits
  and producing a combined oxidative phosphorylation deficiency with a
  characteristic emphasis on complexes I and IV. The biochemical defect is
  markedly tissue-graded - most severe in heart muscle, intermediate in skeletal
  muscle, and borderline in fibroblasts - which explains the cardiac-dominant
  clinical presentation. Affected children present in the neonatal period or
  infancy with hypertrophic cardiomyopathy, mild lactic acidosis, hypoglycemia,
  failure to thrive, and easy fatigue with muscle weakness; cardiac
  decompensation in the first year is often fatal. Individuals who survive
  infancy can develop a slowly progressive multisystem phenotype in the second
  and third decades with hepatopathy, renal insufficiency, myopathy, hemiplegic
  migraine, pigmentary retinopathy, and Leigh-like lesions of the thalami, basal
  ganglia and cerebellum on brain MRI. Fewer than a dozen patients have been
  reported worldwide; the recurrent missense allele c.467T>G, p.(Leu156Arg)
  accounts for the majority of published alleles. No disease-modifying therapy
  exists and management is supportive and cardiac-directed. Note that no
  MRPL44-specific GeneReviews chapter exists; the GeneReviews-tagged reference in
  this entry is the umbrella Primary Mitochondrial Disorders Overview and was not
  used as a phenotype baseline, since its abstract contains no MRPL44-specific
  clinical characteristics.
disease_term:
  preferred_term: Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency
  term:
    id: MONDO:0014162
    label: infantile hypertrophic cardiomyopathy due to MRPL44 deficiency
parents:
- MONDO:0000732
references:
- reference: PMID:23315540
  title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
- reference: PMID:25797485
  title: "MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy."
- reference: PMID:34140213
  title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
- reference: PMID:33742325
  title: "Uniparental isodisomy of chromosome 2 causing MRPL44-related multisystem mitochondrial disease."
- reference: PMID:40402202
  title: "A novel likely pathogenic variant in the mitochondrial ribosomal protein L44 (MRPL44) associated with hypertrophic cardiomyopathy in Tunisian patients."
- reference: DOI:10.1101/2025.09.24.678132
  title: "Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model."
- reference: PMID:20301403
  title: "Primary Mitochondrial Disorders Overview."
  tags:
  - GeneReviews
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  mechanistic_category:
  - classification_value: mitochondrial disease
  icimd_category:
  - classification_value: mitoribosome
    notes: >-
      ICIMD category for disorders of the mitoribosome. MRPL44 encodes mL44, a
      structural protein of the large (39S) subunit of the mitochondrial
      ribosome, so COXPD16 is a mitoribosomal translation defect rather than a
      primary respiratory-chain subunit or assembly-factor disorder.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >
    Ultra-rare. Seven patients from six families were reported between 2013 and
    2021, with a further Tunisian sibling pair reported in 2025. No population
    prevalence, incidence, or carrier frequency estimate exists.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, five patients have been described with pathogenic variants in MRPL44, encoding the ml44 protein which is part of the large subunit of the mitochondrial ribosome (mitoribosome)."
    explanation: >-
      Establishes that only five patients had been published before this 2021
      report added two more, confirming ultra-rare status.
  - reference: PMID:40402202
    reference_title: "A novel likely pathogenic variant in the mitochondrial ribosomal protein L44 (MRPL44) associated with hypertrophic cardiomyopathy in Tunisian patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study reports a novel MRPL44 variant associated with HCM in a Tunisian family."
    explanation: Documents an additional affected family, extending the small published cohort.
progression:
- notes: >
    Bimodal. Infantile-onset disease is dominated by rapidly progressive
    hypertrophic cardiomyopathy; cardiac decompensation within the first year of
    life has been fatal in several reported infants despite inotropes,
    ventricular assist devices, and ECMO. Children who stabilize after the first
    year may remain well with asymptomatic cardiomyopathy into adolescence, and
    at least one case of spontaneous resolution of the cardiomyopathy has been
    described. Survivors homozygous for the recurrent p.Leu156Arg allele
    subsequently develop a slowly progressive multisystem phenotype in the second
    and third decades, with myopathy, exercise intolerance, hepatopathy, renal
    insufficiency, hemiplegic migraine, pigmentary retinopathy, and Leigh-like
    brain MRI lesions. This age-dependent emergence of neurological involvement
    is prognostically important when cardiac transplantation is being considered
    in infancy. No prospective natural-history study, survival estimate, or
    validated prognostic biomarker exists.
  evidence:
  - reference: PMID:25797485
    reference_title: "MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of note, neurological and neuro-ophthalmological impairment seems to be a disease feature of the second and third decades of life, which should be taken into account in patient management and counseling."
    explanation: >-
      Documents the delayed, age-dependent onset of neurological and
      neuro-ophthalmological involvement in survivors.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A decompensation of the cardiac function in the first year resulted in demise."
    explanation: Documents fatal first-year cardiac decompensation in the infantile presentation.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The first child died in infancy of cardiac failure following an acute infection, whereas in her sister the cardiomyopathy stabilized, and she remained well with only asymptomatic cardiomyopathy at the time of publication at age 14 years"
    explanation: >-
      Illustrates the marked intrafamilial variability in course between siblings
      carrying the same genotype.
mechanistic_hypotheses:
- hypothesis_group_id: nutrient_dependent_postnatal_manifestation
  hypothesis_label: >-
    Postnatal glucose-to-fatty-acid fuel switch as the trigger for
    MRPL44 cardiomyopathy manifestation
  status: EMERGING
  description: >
    An emerging model proposes that ATP deficiency alone does not explain why
    MRPL44 hypertrophic cardiomyopathy declares itself around birth. In patient
    iPSC-derived cardiomyocytes, glucose-rich (fetal-like) conditions provoke a
    partly compensatory response - increased mtDNA copy number and mitochondrial
    transcription - whereas lipid-enriched (postnatal-like) conditions instead
    trigger the mitochondrial integrated stress response (ISRmt) with partial ER
    stress, lipid-droplet accumulation, and maladaptive upregulation of lipid
    uptake and cholesterol synthesis genes. On this model the perinatal switch
    to fatty-acid oxidation is the critical window that converts a compensated
    translation defect into hypertrophic disease. This is preprint,
    single-patient-line, in-vitro evidence and does NOT justify any dietary
    intervention.
  evidence:
  - reference: DOI:10.1101/2025.09.24.678132
    reference_title: "Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These observations provide a mechanistic basis for postnatal disease manifestation and highlight nutrient metabolism as a key driver in development of infantile-onset mitochondrial hypertrophic cardiomyopathy."
    explanation: >-
      States the hypothesis directly. Preprint, one patient iPSC line, awaiting
      peer review and replication.
pathophysiology:
- name: Biallelic MRPL44 Loss of Function and mL44 Protein Depletion
  biological_scale: MOLECULAR
  description: >
    Biallelic pathogenic MRPL44 variants - most often the recurrent missense
    c.467T>G, p.(Leu156Arg) - destabilize the mL44 protein rather than abolishing
    its transcription, so patient heart, skeletal muscle, and fibroblasts all show
    sharply reduced steady-state mL44 levels. Frameshift alleles (e.g.
    c.481_484delinsTC, p.Thr161Serfs*2) are predicted to yield no protein at all,
    and a second substitution at the same residue, p.(Leu156Pro), is likewise
    strongly destabilizing. mL44 is a eukaryote-specific component of the large
    mitoribosomal subunit, forms a dimer, localizes to the mitochondrial matrix,
    and sits near the peptide exit channel.
  gene:
    preferred_term: MRPL44
    term:
      id: hgnc:16650
      label: MRPL44
  cellular_components:
  - preferred_term: mitochondrial large ribosomal subunit
    term:
      id: GO:0005762
      label: mitochondrial large ribosomal subunit
  evidence:
  - reference: PMID:23315540
    reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found severely reduced MRPL44 levels in the patient's heart, skeletal muscle and fibroblasts suggesting that the missense mutation affected the protein stability."
    explanation: >-
      Shows that the disease mechanism of the recurrent missense allele is loss
      of mL44 protein stability across all tissues examined.
  - reference: PMID:26221731
    reference_title: "A Role for the Mitochondrial Protein Mrpl44 in Maintaining OXPHOS Capacity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We found that it can form multimers, and confirm that it is part of the large subunit of the mitochondrial ribosome."
    explanation: >-
      Confirms mL44 is a bona fide constituent of the large mitoribosomal
      subunit that oligomerizes.
  - reference: PMID:26221731
    reference_title: "A Role for the Mitochondrial Protein Mrpl44 in Maintaining OXPHOS Capacity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we show by immunofluorescence microscopy and subcellular fractionation that Mrpl44 is localized to the matrix of the mitochondria."
    explanation: Establishes the mitochondrial matrix localization of mL44.
  downstream:
  - target: Large Mitoribosomal Subunit Assembly Defect
    causal_link_type: DIRECT
    description: >-
      Depletion of mL44 removes a structural component of the 39S subunit and
      compromises its assembly and stability.
- name: Large Mitoribosomal Subunit Assembly Defect
  biological_scale: MOLECULAR
  description: >
    Loss of mL44 reduces the amount of assembled large (39S) mitoribosomal
    subunit and destabilizes the mtDNA-encoded 16S rRNA that forms its scaffold,
    while leaving the small (28S) subunit largely intact. Retroviral
    re-expression of wild-type MRPL44 in patient fibroblasts restores the large
    subunit assembly defect, establishing the causal direction.
  cellular_components:
  - preferred_term: mitochondrial large ribosomal subunit
    term:
      id: GO:0005762
      label: mitochondrial large ribosomal subunit
  biological_processes:
  - preferred_term: mitochondrial large ribosomal subunit assembly
    term:
      id: GO:1902775
      label: mitochondrial large ribosomal subunit assembly
    modifier: DECREASED
  evidence:
  - reference: PMID:23315540
    reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In patient fibroblasts, decreased MRPL44 affected assembly of the large ribosomal subunit and stability of 16S rRNA leading to complex IV deficiency."
    explanation: >-
      Directly demonstrates the 39S assembly and 16S rRNA stability defect in
      patient cells.
  - reference: PMID:23315540
    reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Retroviral expression of wild-type MRPL44 in patient fibroblasts rescued the large ribosome assembly defect and COX deficiency."
    explanation: >-
      Genetic complementation establishes that MRPL44 loss is causal for the
      assembly and cytochrome c oxidase defects.
  - reference: PMID:33742325
    reference_title: "Uniparental isodisomy of chromosome 2 causing MRPL44-related multisystem mitochondrial disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These studies confirmed that c.467 T > G affects the stability or assembly of the large subunit of the mitochondrial ribosome, leading to impaired mitochondrial protein synthesis and decreased levels of multiple OXPHOS components."
    explanation: >-
      Independent replication in a second laboratory of the 39S assembly defect
      caused by the recurrent allele.
  downstream:
  - target: Impaired Mitochondrial Translation
    causal_link_type: DIRECT
    description: >-
      Fewer translationally competent mitoribosomes reduce the rate of synthesis
      of mtDNA-encoded polypeptides.
- name: Impaired Mitochondrial Translation
  biological_scale: CELLULAR
  description: >
    The assembly defect lowers mitochondrial protein synthesis, measured by
    35S-amino-acid incorporation into mtDNA-encoded polypeptides in patient
    fibroblasts. The reduction affects all thirteen mtDNA-encoded subunits rather
    than a single complex, and its magnitude tracks the severity of the
    underlying genotype - a null/missense compound heterozygote had roughly a
    third of control incorporation, while a missense/missense compound
    heterozygote retained more. mL44 sits at the peptide exit tunnel, and the
    original report noted the assembly defect exceeded the de novo translation
    defect in fibroblasts, suggesting an additional role in the folding or
    stability of nascent polypeptides as they leave the ribosome.
  biological_processes:
  - preferred_term: mitochondrial translation
    term:
      id: GO:0032543
      label: mitochondrial translation
    modifier: DECREASED
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We show this to be caused by reduced mitochondrial DNA encoded protein synthesis affecting all subunits, and resulting in dysfunction of complex I and IV assembly."
    explanation: >-
      Establishes globally reduced mtDNA-encoded protein synthesis as the
      proximate cause of the OXPHOS assembly defects.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The degree of oxidative phosphorylation dysfunction correlated with the impairment of mitochondrial protein synthesis due to different pathogenic variants."
    explanation: >-
      Demonstrates a genotype-to-translation-to-OXPHOS dose relationship across
      alleles.
  - reference: PMID:23315540
    reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "Despite this assembly defect, de novo mitochondrial translation was only mildly affected in fibroblasts suggesting that MRPL44 may have a function in the assembly/stability of nascent mitochondrial polypeptides exiting the ribosome."
    explanation: >-
      Qualifies the translation defect - in fibroblasts of the index family the
      de novo translation deficit was mild, raising an additional peptide-exit
      chaperoning role for mL44.
  downstream:
  - target: Failed Compensatory mtDNA Replication and Transcription
    causal_link_type: DIRECT
    hypothesis_groups:
    - nutrient_dependent_postnatal_manifestation
    description: >-
      Cardiomyocytes respond to the translation block by amplifying mtDNA and
      mitochondrial transcripts, a response that cannot restore protein output.
      Hypothesis-tagged: rests on a single unreviewed patient iPSC-cardiomyocyte
      study, and a mouse NIH3T3 knockdown study found no mtDNA copy-number effect.
  - target: Combined Complex I and IV Deficiency
    causal_link_type: DIRECT
    description: >-
      Reduced supply of mtDNA-encoded subunits prevents assembly of the
      respiratory chain complexes that contain them.
- name: Failed Compensatory mtDNA Replication and Transcription
  biological_scale: CELLULAR
  description: >
    In MRPL44-mutant patient iPSC-derived cardiomyocytes grown in glucose-rich
    (fetal-like) medium, mtDNA copy number rises about 2.5-fold and mtDNA-encoded
    transcripts - particularly complex I and complex V subunits - are strongly
    induced, with increased mitochondrial content per cell. Despite this
    transcriptional and replicative upregulation, steady-state complex I protein
    remains markedly reduced: the cell mounts a mitochondrial biogenesis response
    that operates upstream of, and therefore cannot bypass, the translation
    block. This is the cellular counterpart of the mitochondrial proliferation
    seen ultrastructurally in patient myocardium.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: mitochondrial DNA replication
    term:
      id: GO:0006264
      label: mitochondrial DNA replication
    modifier: INCREASED
  - preferred_term: mitochondrial transcription
    term:
      id: GO:0006390
      label: mitochondrial transcription
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1101/2025.09.24.678132
    reference_title: "Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The patient CMs showed an increase of 2.5-fold in mtDNA copy number compared to controls"
    explanation: >-
      Quantifies the compensatory mtDNA amplification in patient cardiomyocytes.
      Preprint evidence from a single patient iPSC line.
  - reference: DOI:10.1101/2025.09.24.678132
    reference_title: "Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Despite this transcriptional upregulation, steady-state complex I protein level was markedly reduced"
    explanation: >-
      Shows the compensatory response fails to restore OXPHOS subunit protein.
      Preprint evidence.
  - reference: PMID:26221731
    reference_title: "A Role for the Mitochondrial Protein Mrpl44 in Maintaining OXPHOS Capacity."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "Thus, Mrpl44 appears to regulate mitochondrial genome expression rather than copy number."
    explanation: >-
      Counterpoint - in mouse NIH3T3 cells, altering Mrpl44 expression changed
      mitochondrial gene expression but NOT mtDNA copy number. Scored PARTIAL
      rather than REFUTE because the systems differ (rodent knockdown/
      overexpression versus a human p.Leu156Arg iPSC-cardiomyocyte), but it means
      the compensatory mtDNA amplification is not yet an established feature of
      MRPL44 deficiency.
  downstream:
  - target: Nutrient-Dependent Metabolic Stress Response in Cardiomyocytes
    causal_link_type: DIRECT
    hypothesis_groups:
    - nutrient_dependent_postnatal_manifestation
    description: >-
      Compensation that suffices under fetal glucose-based fuel fails when the
      postnatal heart switches to fatty-acid oxidation.
- name: Nutrient-Dependent Metabolic Stress Response in Cardiomyocytes
  biological_scale: CELLULAR
  description: >
    Under lipid-enriched (postnatal-like) conditions, MRPL44-mutant iPSC
    cardiomyocytes activate the mitochondrial integrated stress response (ISRmt)
    - ATF5 with its targets TRIB3, ASNS, MTHFD2 and GDF15, plus DDIT3, the de
    novo serine biosynthesis genes PSAT1/PSPH and CEBPG - alongside partial ER
    stress (HERPUD1, NUPR1, XBP1, CHAC1, HSPA5, without XBP1 splicing). FGF21
    induction is notably absent. The cells simultaneously accumulate lipid
    droplets and upregulate lipid-uptake and cholesterol-synthesis genes, a
    maladaptive rewiring that the authors link to persistent anabolic signaling
    rather than to ATP deficiency alone. This node is hypothesis-tagged:
    the evidence is preprint, in vitro, and from one patient genotype.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: fatty acid beta-oxidation
    term:
      id: GO:0006635
      label: fatty acid beta-oxidation
    modifier: DECREASED
  evidence:
  - reference: DOI:10.1101/2025.09.24.678132
    reference_title: "Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In contrast the lipid-enriched medium triggered both mitochondrial and endoplasmic reticulum -related stress responses, disrupted lipid and cholesterol homeostasis, accompanied by remodeling of the central biosynthetic pathway of one carbon metabolism."
    explanation: >-
      Documents the nutrient-conditional stress response. Preprint, in vitro,
      single patient line.
  - reference: DOI:10.1101/2025.09.24.678132
    reference_title: "Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The cells accumulated lipids while also inducing lipid uptake and synthesis genes, suggesting maladaptive metabolic rewiring."
    explanation: Documents the maladaptive lipid handling in mutant cardiomyocytes.
  - reference: DOI:10.1101/2025.09.24.678132
    reference_title: "Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Mitochondrial ribosome defect disrupts lipid homeostasis in cardiomyocytes causing impaired fatty acid oxidation, lipid accumulation and altered cholesterol metabolism."
    explanation: >-
      Directly supports the decreased fatty acid beta-oxidation annotation on
      this node. Preprint, in vitro, single patient line.
  downstream:
  - target: Cardiomyocyte Bioenergetic Failure and Mitochondrial Proliferation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - nutrient_dependent_postnatal_manifestation
    intermediate_mechanisms:
    - Persistent ISRmt and mTORC1-linked anabolic signaling
    - Lipid droplet accumulation and impaired fatty-acid utilization
    description: >-
      Proposed route by which nutrient-conditional stress signaling, not ATP
      deficit alone, drives pathological hypertrophic growth.
- name: Combined Complex I and IV Deficiency
  biological_scale: CELLULAR
  description: >
    Because only complexes I, III, IV, and V contain mtDNA-encoded subunits, the
    translation defect produces a combined rather than isolated respiratory chain
    deficiency, with a reproducible emphasis on complex IV and complex I.
    Blue-native PAGE shows incompletely assembled complex I and reduced complex IV
    holocomplex, MT-CO1 protein is reduced while the nuclear-encoded ATP5F1B is
    normal, and high-resolution respirometry shows deficient complex I- and
    complex IV-linked oxygen consumption. The disproportionate complex IV
    involvement is unexplained, since the measured synthesis rates of complex I
    and complex IV subunits are similarly reduced.
  biological_processes:
  - preferred_term: mitochondrial respiratory chain complex I assembly
    term:
      id: GO:0032981
      label: mitochondrial respiratory chain complex I assembly
    modifier: DECREASED
  - preferred_term: mitochondrial respiratory chain complex IV assembly
    term:
      id: GO:0033617
      label: mitochondrial respiratory chain complex IV assembly
    modifier: DECREASED
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  evidence:
  - reference: PMID:23315540
    reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of respiratory chain enzymes revealed a combined deficiency of complexes I and IV in the heart and skeletal muscle."
    explanation: The defining biochemical signature of MRPL44 deficiency in patient tissue.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We document a combined respiratory chain enzyme deficiency with emphasis on complex I and IV, affecting heart muscle tissue more than skeletal muscle or fibroblasts."
    explanation: >-
      Replicates the combined CI/CIV deficiency and establishes its tissue
      gradient.
  - reference: PMID:26221731
    reference_title: "A Role for the Mitochondrial Protein Mrpl44 in Maintaining OXPHOS Capacity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This ultimately impacted ATP synthesis capability and respiratory capacity of cells."
    explanation: >-
      Independent experimental manipulation of Mrpl44 expression reproduces the
      OXPHOS capacity defect.
  downstream:
  - target: Cardiomyocyte Bioenergetic Failure and Mitochondrial Proliferation
    causal_link_type: DIRECT
    description: >-
      The energy-demanding myocardium is the tissue least able to tolerate the
      OXPHOS deficit.
  - target: Systemic Energy Deficit and Late Multisystem Involvement
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Chronic partial ATP deficit in skeletal muscle, liver, kidney, retina and brain
    - Cumulative injury of post-mitotic high-demand tissues over years
    description: >-
      Lower-threshold tissues decompensate only after prolonged exposure to the
      partial OXPHOS deficit, giving a second- and third-decade multisystem
      phenotype.
- name: Cardiomyocyte Bioenergetic Failure and Mitochondrial Proliferation
  biological_scale: TISSUE
  conforms_to: "cardiomyopathy_maladaptive_remodeling#Primary Cardiomyocyte Insult"
  description: >
    Cardiac muscle shows the most profound enzyme deficiency of any tissue
    examined, with a profound decrease in complex IV, a strong decrease in
    complex I, and incompletely assembled complex V. Electron microscopy of the
    myocardium shows a diffuse proliferation of enlarged, atypically shaped
    mitochondria with aberrant cristae that displace and replace contractile
    elements - the structural correlate of compensatory mitochondrial biogenesis
    failing to restore ATP supply. The result is hypertrophic remodelling and
    progressive contractile failure of the neonatal and infant heart.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The enzyme deficiency was most pronounced in cardiac muscle tissue, where there was massive proliferation of mitochondria on electron microscopy displacing contractile elements."
    explanation: >-
      Links the tissue-graded biochemical defect to the cardiac structural
      pathology.
  - reference: PMID:23315540
    reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings indicate that mitochondrial ribosomal subunit defects can generate tissue-specific manifestations, such as cardiomyopathy."
    explanation: >-
      Frames the cardiac-selective manifestation as the central conceptual
      finding of MRPL44 deficiency.
  downstream:
  - target: Progressive Heart Failure
    causal_link_type: DIRECT
    description: Loss of contractile mass and hypertrophic remodelling reduce cardiac output.
- name: Progressive Heart Failure
  biological_scale: ORGANISM
  conforms_to: "cardiomyopathy_maladaptive_remodeling#Structural Cardiac Impairment and Heart Failure"
  description: >
    Hypertrophic cardiomyopathy in MRPL44 deficiency progresses to overt
    ventricular dysfunction, cardiomegaly, and in the most severe infantile cases
    cardiogenic shock with secondary hepatic and renal failure requiring
    inotropes, ventricular assist devices, and extracorporeal membrane
    oxygenation. Some infants stabilize after the first year and remain
    asymptomatic into adolescence.
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "she was readmitted in cardiogenic shock, hypotensive, hypoglycemic, lethargic and hypoxic, likely due to right ventricular failure."
    explanation: >-
      Documents progression from compensated hypertrophic cardiomyopathy to
      cardiogenic shock with right ventricular failure. (The same report records
      that this infant subsequently died; the fatal outcome is cited separately
      under the mechanical circulatory support treatment.)
- name: Systemic Energy Deficit and Late Multisystem Involvement
  biological_scale: ORGANISM
  description: >
    Outside the heart the same combined OXPHOS deficiency produces a
    lower-grade, cumulative energy deficit. In skeletal muscle it manifests as
    exercise intolerance, easy fatigue, and myopathy; in liver as steatosis with
    elevated transaminases; in kidney as renal insufficiency; and in the central
    nervous system and retina - typically only in the second and third decades -
    as hemiplegic migraine, transient hemiparesis and confusion, spasticity,
    ataxia, pigmentary retinopathy, and Leigh-like lesions of the thalami, basal
    ganglia, midbrain and cerebellum.
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  evidence:
  - reference: PMID:25797485
    reference_title: "MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."
    explanation: Enumerates the late multisystem features of MRPL44 deficiency.
  - reference: PMID:33742325
    reference_title: "Uniparental isodisomy of chromosome 2 causing MRPL44-related multisystem mitochondrial disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "confirms that MRLP44 mutations cause a mitochondrial translation defect that may present as a multisystem disorder with neurological involvement."
    explanation: >-
      Independent confirmation that the translation defect can present as
      multisystem disease with neurological involvement.
phenotypes:
- category: Cardiovascular
  name: Hypertrophic Cardiomyopathy
  description: >
    Hypertrophic cardiomyopathy of neonatal or infantile onset is the core and
    most consistent clinical feature of MRPL44 deficiency, present in every
    reported patient. Onset has ranged from the neonatal period to age 21 years,
    where subclinical cardiac hypertrophy was recognized in an adult who
    presented with skeletal myopathy.
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:25797485
    reference_title: "MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both patients presented with childhood-onset hypertrophic cardiomyopathy, which seems to be the core clinical feature associated with MRPL44 deficiency."
    explanation: >-
      Explicitly identifies hypertrophic cardiomyopathy as the core feature,
      supporting a VERY_FREQUENT frequency band.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients presented as children with hypertrophic cardiomyopathy, had mild lactic acidosis, and easy fatigue and muscle weakness."
    explanation: >-
      Confirms hypertrophic cardiomyopathy in all five previously published
      patients (5/5). The literature term "all" would map to OBLIGATE, but
      VERY_FREQUENT is used deliberately as the conservative band because the
      denominator is a nine-patient literature total, not a systematically
      ascertained cohort.
- category: Cardiovascular
  name: Left Ventricular Hypertrophy
  description: >
    Echocardiographic left ventricular hypertrophy with depressed ejection
    fraction is the objective correlate of the cardiomyopathy, detected as early
    as the neonatal period.
  phenotype_term:
    preferred_term: Left ventricular hypertrophy
    term:
      id: HP:0001712
      label: Left ventricular hypertrophy
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an echocardiogram revealed an ejection fraction of 25% (normal 55–70%) with left ventricular dysfunction and hypertrophy"
    explanation: >-
      Documents echocardiographic left ventricular dysfunction and hypertrophy in
      an affected infant.
- category: Cardiovascular
  name: Congestive Heart Failure
  description: >
    Cardiac decompensation with reduced ejection fraction, cardiomegaly, and in
    the most severe infants cardiogenic shock requiring mechanical circulatory
    support. Fatal in the first year of life in several reported patients.
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She had cardiomegaly on chest X-ray, and echocardiography showed a very restrictive right ventricle and a ballooned left ventricle with barely any unmeasurable contraction and blood flow, and she died in cardiac failure shortly after."
    explanation: Documents fatal congestive cardiac failure in an infant with MRPL44 deficiency.
- category: Metabolic
  name: Lactic Acidosis
  description: >
    Mild to marked lactic acidosis reflects the respiratory chain block. Reported
    across the cohort as mild lactic acidosis; one neonate presented on the
    second day of life with Kussmaul breathing, severe metabolic acidosis, and an
    elevated lactate/pyruvate ratio.
  phenotype_term:
    preferred_term: Lactic acidosis
    term:
      id: HP:0003128
      label: Lactic acidosis
  frequency: FREQUENT
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three presented as infants with hypertrophic cardiomyopathy, mild lactic acidosis, and easy fatigue and muscle weakness, whereas two presented in adolescence with myopathy and neurological symptoms."
    explanation: >-
      Documents lactic acidosis in three of the five previously reported patients
      plus one of the two new infants (4/7 = 57%), a derived count supporting the
      FREQUENT band (30-79%). Note the same paper's body text states that "All
      patients ... had mild lactic acidosis", conflicting with its own abstract;
      the lower abstract count is used as the conservative basis.
- category: Metabolic
  name: Hypoglycemia
  description: >
    Recurrent, often asymptomatic hypoglycemia was documented in both infants of
    the 2021 series, in one requiring continuous intravenous glucose in the
    neonatal period. Insulin, cortisol, and growth hormone responses during
    hypoglycemia were appropriate, excluding hyperinsulinism.
  phenotype_term:
    preferred_term: Hypoglycemia
    term:
      id: HP:0001943
      label: Hypoglycemia
    temporality: RECURRENT
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe two infants who presented with cardiomyopathy from the neonatal period, failure to thrive, hypoglycemia and in one infant lactic acidosis."
    explanation: Documents hypoglycemia as part of the infantile presentation.
- category: Growth
  name: Failure to Thrive
  description: >
    Poor growth with feeding difficulties requiring nasogastric or gastrostomy
    feeding was prominent in the infantile presentation.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe two infants who presented with cardiomyopathy from the neonatal period, failure to thrive, hypoglycemia and in one infant lactic acidosis."
    explanation: Documents failure to thrive in the infantile presentation.
- category: Musculoskeletal
  name: Muscle Weakness
  description: >
    Easy fatigue and proximal muscle weakness are reported across the cohort and
    become the dominant complaint in patients who survive infancy, evolving into
    a skeletal myopathy in adolescence and adulthood.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients presented as children with hypertrophic cardiomyopathy, had mild lactic acidosis, and easy fatigue and muscle weakness."
    explanation: >-
      Reports easy fatigue and muscle weakness in all five previously published
      patients (5/5). Mapped to VERY_FREQUENT (80-100%) rather than OBLIGATE
      because the two infants added by this 2021 report were not separately
      scored for weakness.
- category: Musculoskeletal
  name: Myopathy
  description: >
    A skeletal myopathy distinct from the cardiomyopathy becomes the dominant
    manifestation in patients who survive infancy: the two adolescent- and
    adult-onset patients presented with myopathy and neurological symptoms rather
    than with heart failure.
  phenotype_term:
    preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three presented as infants with hypertrophic cardiomyopathy, mild lactic acidosis, and easy fatigue and muscle weakness, whereas two presented in adolescence with myopathy and neurological symptoms."
    explanation: >-
      Documents myopathy as the presenting feature of the two later-onset
      patients, distinguishing the adolescent/adult phenotype from the infantile
      cardiac-dominant one.
- category: Musculoskeletal
  name: Exercise Intolerance
  description: >
    Exercise intolerance is a defining feature of the skeletal-muscle arm of the
    disease and was the presenting complaint of the young adult reported with
    subclinical cardiac hypertrophy.
  phenotype_term:
    preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
  evidence:
  - reference: ORPHA:352563
    reference_title: "Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hypertrophic cardiomyopathy, hepatic steatosis with elevated liver transaminases, exercise intolerance and muscle weakness"
    explanation: >-
      The Orphanet clinical definition of COXPD16 lists exercise intolerance as a
      characteristic feature.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A fifth patient presented as a young adult with skeletal myopathy and exercise intolerance, subclinical cardiac hypertrophy recognized at age 21 years"
    explanation: Documents exercise intolerance as a presenting adult feature.
- category: Hepatic
  name: Hepatic Steatosis
  description: >
    Hepatic involvement ranges from mild liver disease to hepatic steatosis with
    elevated transaminases; secondary hepatic failure also occurs during terminal
    cardiogenic shock.
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: ORPHA:352563
    reference_title: "Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare mitochondrial oxidative phosphorylation disorder with complex I and IV deficiency characterized by hypertrophic cardiomyopathy, hepatic steatosis with elevated liver transaminases, exercise intolerance and muscle weakness."
    explanation: >-
      Orphanet's expert clinical definition includes hepatic steatosis with
      elevated liver transaminases as a characteristic feature.
  - reference: PMID:25797485
    reference_title: "MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."
    explanation: >-
      The primary report documents hepatopathy but does not itself specify
      steatosis, so this is scored PARTIAL for the steatosis claim.
- category: Hepatic
  name: Elevated Hepatic Transaminases
  description: >
    Elevated serum liver transaminases accompany the hepatic involvement of
    MRPL44 deficiency.
  phenotype_term:
    preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  evidence:
  - reference: ORPHA:352563
    reference_title: "Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "hepatic steatosis with elevated liver transaminases"
    explanation: Orphanet clinical definition lists elevated liver transaminases.
- category: Renal
  name: Renal Insufficiency
  description: >
    Renal insufficiency has been reported as part of the late multisystem
    phenotype; acute renal dysfunction also occurs secondary to cardiogenic shock.
  phenotype_term:
    preferred_term: Renal insufficiency
    term:
      id: HP:0000083
      label: Renal insufficiency
  evidence:
  - reference: PMID:25797485
    reference_title: "MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."
    explanation: >-
      Reports renal insufficiency among the additional features of the two
      patients in this series. No frequency band is assigned: the source
      enumerates features without per-patient attribution or any count, so any
      band would be unsupported.
- category: Ophthalmological
  name: Pigmentary Retinopathy
  description: >
    Pigmentary retinopathy (tapetoretinal dystrophy) is one of the
    neuro-ophthalmological features that emerge in the second and third decades
    of life in patients who survive infantile cardiomyopathy.
  phenotype_term:
    preferred_term: Pigmentary retinopathy
    term:
      id: HP:0000580
      label: Pigmentary retinopathy
  evidence:
  - reference: PMID:25797485
    reference_title: "MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."
    explanation: >-
      Reports pigmentary retinopathy among the late features observed in this
      two-patient series. No frequency band is assigned - the source gives no
      count or qualitative frequency term.
- category: Neurological
  name: Hemiplegic Migraine
  description: >
    Hemiplegic migraine with transient episodes of hemiparesis and confusion has
    been reported in older MRPL44-deficient patients, typically alongside
    Leigh-like brain MRI lesions.
  phenotype_term:
    preferred_term: Hemiplegic migraine
    term:
      id: HP:0002076
      label: Migraine
  evidence:
  - reference: PMID:25797485
    reference_title: "MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, we observed several additional clinical signs and symptoms including pigmentary retinopathy, hemiplegic migraine, Leigh-like lesions on brain MRI, renal insufficiency, and hepatopathy."
    explanation: >-
      Documents hemiplegic migraine as a late feature in this two-patient series.
      No frequency band is assigned - the source gives no count. HPO has no
      dedicated hemiplegic migraine term, so the generic Migraine term is used
      with a more specific preferred_term.
- category: Neurological
  name: Ataxia
  description: >
    Ataxia and spasticity were described in the young adult with cerebellar and
    subcortical white matter lesions on brain MRI.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "transient episodes of neurological dysfunction of hemiparesis and confusion, spasticity and ataxia, and on brain MRI lesions in basal ganglia, thalami and midbrain and subcortical and cerebellar white matter"
    explanation: >-
      Documents ataxia in a single adult patient. Per the frequency guidelines a
      single case maps to "omit frequency", so no band is assigned.
- category: Neurological
  name: Spasticity
  description: >
    Spasticity accompanied the ataxia and Leigh-like MRI changes in the adult
    multisystem presentation.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "transient episodes of neurological dysfunction of hemiparesis and confusion, spasticity and ataxia, and on brain MRI lesions in basal ganglia, thalami and midbrain and subcortical and cerebellar white matter"
    explanation: Documents spasticity in the adult multisystem presentation.
- category: Neurodevelopmental
  name: Learning Difficulties
  description: >
    Learning difficulties were reported in one adolescent-onset patient. Cognitive
    function was explicitly normal in the infantile-onset children, and one adult
    developed reduced processing speed and executive function only later, so
    global developmental delay is not a general feature of MRPL44 deficiency.
  phenotype_term:
    preferred_term: Specific learning disability
    term:
      id: HP:0001328
      label: Specific learning disability
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The fourth patient from age 14 years on developed cardiomyopathy, hemiplegic migraines, learning difficulties, myopathy, tapetoretinal dystrophy, and Leigh-like lesions in thalami, basal ganglia and cerebellum on brain MRI"
    explanation: Documents learning difficulties in a single adolescent-onset patient.
imaging_findings:
- name: Leigh-Like Lesions on Brain MRI
  modality: MRI
  description: >
    Symmetric signal abnormalities of the thalami, basal ganglia, midbrain, and
    cerebellar and subcortical white matter resembling Leigh syndrome have been
    documented in older MRPL44-deficient patients. No brain MRI abnormality has
    been reported in the infantile cardiac-dominant presentation, but infant
    neuroimaging is sparse - one neonate had a normal cranial ultrasound and no
    infant brain MRI has been published, so the apparent sparing is unconfirmed.
  phenotype_term:
    preferred_term: Abnormal basal ganglia MRI signal intensity
    term:
      id: HP:0012751
      label: Abnormal basal ganglia MRI signal intensity
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "transient episodes of neurological dysfunction of hemiparesis and confusion, spasticity and ataxia, and on brain MRI lesions in basal ganglia, thalami and midbrain and subcortical and cerebellar white matter"
    explanation: Describes the distribution of the Leigh-like MRI lesions.
  - reference: ORPHA:352563
    reference_title: "Infantile hypertrophic cardiomyopathy due to MRPL44 deficiency"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neuro-opthalmological features (hemiplegic migraine, Leigh-like lesions on brain MRI, pigmentary retinopathy) have been reported later in life."
    explanation: >-
      Orphanet's clinical definition lists Leigh-like brain MRI lesions as a
      late-onset feature.
- name: Cardiomegaly on Chest Radiograph
  modality: XRAY
  description: >
    Cardiomegaly on plain chest radiography was the first objective sign of
    cardiac involvement in one infant, prompting the echocardiogram that revealed
    left ventricular hypertrophy and a depressed ejection fraction.
  phenotype_term:
    preferred_term: Cardiomegaly
    term:
      id: HP:0001640
      label: Cardiomegaly
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a chest radiograph identified cardiomegaly and an echocardiogram revealed an ejection fraction of 25%"
    explanation: Documents radiographic cardiomegaly with echocardiographic confirmation.
histopathology:
- name: Mitochondrial Proliferation with Aberrant Cristae in Cardiomyocytes
  description: >
    Electron microscopy of myocardial biopsy shows a diffuse proliferation of
    enlarged, atypically shaped mitochondria with aberrant cristae together with
    areas of contractile element loss - the classic ultrastructural picture of a
    mitochondrial cardiomyopathy.
  diagnostic: true
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In Patient 1, on electron microscopy, the heart showed areas of contractile element loss within the cardiomyocytes and a diffuse proliferation of enlarged, atypically shaped mitochondria with aberrant cristae, typical for a mitochondrial cardiomyopathy"
    explanation: Direct ultrastructural description of the cardiac histopathology.
- name: Abnormal Skeletal Muscle Mitochondria without Ragged Red Fibers
  description: >
    Skeletal muscle shows abnormal mitochondria with granular content and
    abnormal cristae, and enlarged mitochondria in some fibers. Notably, Gomori
    trichrome staining did not reveal ragged blue fibers and there were no
    cytochrome c oxidase-negative fibers, so routine mitochondrial muscle
    histochemistry can be unrevealing in MRPL44 deficiency.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In Patient 2, on light microscopy skeletal muscle showed abnormal mitochondria with granular content and abnormal cristae, and in some fibers enlarged mitochondria were noted."
    explanation: Describes the skeletal muscle mitochondrial abnormalities.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gomori trichrome staining did not reveal ragged blue fibers, and there were no cytochrome c oxidase negative fibers."
    explanation: >-
      Establishes that the standard mitochondrial myopathy histochemical markers
      may be absent, an important diagnostic caveat.
biochemical:
- name: Increased circulating lactate concentration
  presence: INCREASED
  context: >
    Elevated blood lactate, generally mild but occasionally severe. One neonate
    had persistent lactic acidemia of 3.3 to 15 mmol/L unrelated to feeding, with
    an elevated lactate/pyruvate ratio indicating a respiratory chain rather than
    a pyruvate dehydrogenase defect.
  biomarker_term:
    preferred_term: Increased circulating lactate concentration
    term:
      id: HP:0002151
      label: Increased circulating lactate concentration
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The persistent lactic acidemia (3.3 to 15 mmol/L, normal < 2 mM) did not change in relation to feeding"
    explanation: Quantifies the persistent elevation of blood lactate.
- name: Reduced cytochrome c oxidase (complex IV) enzyme activity
  presence: DECREASED
  biomarker_term:
    preferred_term: Decreased activity of mitochondrial complex IV
    term:
      id: HP:0008347
      label: Decreased activity of mitochondrial complex IV
  context: >
    The most consistently and most severely reduced respiratory chain activity.
    In cardiac tissue complex IV activity is profoundly decreased; in skeletal
    muscle it is severely to mildly decreased; in fibroblasts it is only
    borderline low, and may only be detectable in a mitochondrial isolate rather
    than a whole-cell homogenate.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in Patient 1 respiratory chain enzyme activities showed a combined deficiency of the activities of respiratory chain enzyme complexes in heart tissue, with a profound decrease in complex IV and a strong decrease in complex I, and a mild decrease of complex II-III"
    explanation: Quantifies the tissue-specific respiratory chain enzyme deficiencies.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In fibroblasts the respiratory chain enzyme activities were normal in the 600 × g homogenate, but showed low complex IV activity in a mitochondrial isolate."
    explanation: >-
      Important diagnostic caveat - fibroblast whole-homogenate assays can miss
      the complex IV defect.
- name: Reduced NADH:ubiquinone oxidoreductase (complex I) enzyme activity
  presence: DECREASED
  biomarker_term:
    preferred_term: Decreased activity of mitochondrial complex I
    term:
      id: HP:0011923
      label: Decreased activity of mitochondrial complex I
  context: >
    Complex I activity is strongly reduced in cardiac tissue and mildly to
    moderately reduced in skeletal muscle, completing the combined complex I and
    IV deficiency signature.
  evidence:
  - reference: PMID:23315540
    reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of respiratory chain enzymes revealed a combined deficiency of complexes I and IV in the heart and skeletal muscle."
    explanation: Documents combined complex I and IV deficiency in patient heart and muscle.
- name: Reduced mitochondrial protein synthesis in fibroblasts
  presence: DECREASED
  context: >
    Quantitative 35S-amino-acid incorporation into mtDNA-encoded polypeptides is
    reduced to approximately one third of control values in fibroblasts from a
    patient with a missense/frameshift genotype, and to approximately half in a
    patient with a missense/missense genotype - a functional assay that both
    confirms the translation defect and grades allele severity.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "clearly decreased synthesis of mitochondrial proteins at 2.23 ± 0.48 fmol AA/μg protein, 33% of the average incorporation (p<0.01)"
    explanation: >-
      Quantifies the translation deficit in the missense/frameshift patient's
      fibroblasts at 33% of control incorporation.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The degree of oxidative phosphorylation dysfunction correlated with the impairment of mitochondrial protein synthesis due to different pathogenic variants."
    explanation: >-
      Establishes the quantitative translation assay as a genotype-severity
      readout.
- name: Reduced MT-CO1 protein with preserved nuclear-encoded ATP5F1B
  presence: DECREASED
  context: >
    Western blotting shows reduced MT-CO1 (a mtDNA-encoded complex IV subunit) in
    all tissues examined while the nuclear-encoded ATP synthase subunit ATP5F1B
    is normal - a discriminating pattern that localizes the defect to
    mitochondrial rather than cytosolic translation.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The amount of MT-CO1 was decreased in all tissues, but the amount of ATP5FB1 was normal"
    explanation: >-
      Demonstrates selective loss of a mtDNA-encoded subunit with preservation of
      a nuclear-encoded one.
genetic:
- name: MRPL44 biallelic pathogenic variants
  gene_term:
    preferred_term: MRPL44
    term:
      id: hgnc:16650
      label: MRPL44
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    MRPL44 (2q36.1) encodes mL44, a 39S mitoribosomal subunit protein with an
    RNase III-like domain spanning residues 86-228. The three functionally
    characterised disease alleles (p.Leu156Arg, p.Leu156Pro, p.Thr161Serfs*2) lie
    in or immediately adjacent to the conserved hydrophobic pocket of that domain
    and have all been shown to reduce mL44 protein abundance. The remaining two
    reported alleles, p.Arg78Gln and p.(Trp66_His69delinsCysAsn), lie outside the
    RNase III-like domain and have not been functionally assayed, so no protein
    abundance claim is made for them. No validated modifier gene, susceptibility
    locus, or protective allele is known, and no reliable gnomAD allele
    frequencies have been published for the disease alleles.
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    description: >
      Disease requires biallelic MRPL44 variants - homozygous in consanguineous
      or founder settings, compound heterozygous otherwise. One reported patient
      became homozygous through complete maternal uniparental isodisomy of
      chromosome 2 rather than by biparental transmission, so a homozygous MRPL44
      result with only one carrier parent should prompt uniparental disomy
      testing (and altered recurrence-risk counselling) rather than being
      dismissed as non-paternity.
    evidence:
    - reference: PMID:23315540
      reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We investigated the genetic basis for infantile onset recessive hypertrophic cardiomyopathy in two siblings."
      explanation: Establishes recessive inheritance in the index sibship.
    - reference: PMID:33742325
      reference_title: "Uniparental isodisomy of chromosome 2 causing MRPL44-related multisystem mitochondrial disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Short-tandem repeat and genome-wide SNP microarray analyses of the family trio confirmed complete maternal uniparental isodisomy of chromosome 2."
      explanation: >-
        Documents uniparental isodisomy as an alternative route to MRPL44
        homozygosity, with direct counselling implications.
  variants:
  - name: MRPL44 c.467T>G, p.(Leu156Arg)
    description: >
      The recurrent missense allele, present in 9 of the first 10 published
      disease alleles. It is located in the conserved hydrophobic pocket of the
      RNase III-like domain and strongly reduces mL44 protein levels while
      leaving some residual protein and activity. Homozygotes have been reported
      with both fatal infantile cardiomyopathy and with later-onset multisystem
      disease, so genotype alone does not predict the clinical course.
    gene:
      preferred_term: MRPL44
      term:
        id: hgnc:16650
        label: MRPL44
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:23315540
      reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Exome sequencing uncovered a homozygous mutation (L156R) in MRPL44 of both siblings."
      explanation: First identification of the recurrent p.Leu156Arg allele.
    - reference: PMID:34140213
      reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The variant c.467T>G; p.(Leu156Arg) is a commonly recurring causal pathogenic variant present in 9 of 10 alleles published"
      explanation: Quantifies the dominance of this allele in the published cohort.
  - name: MRPL44 c.233G>A, p.(Arg78Gln)
    description: >
      A missense allele identified in compound heterozygosity with the recurrent
      p.Leu156Arg variant in a patient with childhood-onset hypertrophic
      cardiomyopathy plus late multisystem features. No clinical_significance is
      recorded here deliberately: unlike the other four alleles, p.Arg78Gln has
      never been assigned a formal ACMG classification in the literature and has
      not been functionally assayed (no protein-abundance, mitoribosome-assembly,
      or translation data exist for it), so any classification would be curator
      invention rather than a sourced claim.
    gene:
      preferred_term: MRPL44
      term:
        id: hgnc:16650
        label: MRPL44
    evidence:
    - reference: PMID:25797485
      reference_title: "MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "we identified two further unrelated patients harboring the previously reported mutation c.467T > G, p.Leu156Arg in MRPL44 in the homozygous state and compound heterozygous with a novel missense mutation c.233G > A, p.Arg78Gln, respectively."
      explanation: Reports the p.Arg78Gln allele in trans with p.Leu156Arg.
  - name: MRPL44 c.481_484delinsTC, p.(Thr161Serfs*2)
    description: >
      A frameshift allele predicted to trigger nonsense-mediated decay or produce
      a premature stop codon, i.e. a true null. In trans with p.Leu156Arg it
      produced the most severe biochemical phenotype in the published series -
      mitochondrial protein synthesis at roughly a third of controls - and fatal
      infantile cardiomyopathy.
    gene:
      preferred_term: MRPL44
      term:
        id: hgnc:16650
        label: MRPL44
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:34140213
      reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The variant in Patient 1 c.481_484delinsTC p.Thr161Serfs*2 is predicted to cause either nonsense-mediated mRNA decay or a premature stop codon."
      explanation: Defines this allele as a predicted null.
  - name: MRPL44 c.467T>C, p.(Leu156Pro)
    description: >
      A second substitution at the recurrent Leu156 residue. Proline substitutions
      are strongly disruptive of secondary structure, and this allele results in
      strongly decreased but not absent mL44 protein.
    gene:
      preferred_term: MRPL44
      term:
        id: hgnc:16650
        label: MRPL44
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:34140213
      reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The additional variant in Patient 2 affected the same amino acid Leu156, but the change was to proline instead of arginine."
      explanation: Documents a second pathogenic substitution at the Leu156 hotspot.
  - name: MRPL44 c.198_205delinsTA, p.(Trp66_His69delinsCysAsn)
    description: >
      A homozygous delins allele reported in a Tunisian family with severe
      hypertrophic cardiomyopathy affecting two siblings. It shortens the protein
      and was absent from ClinVar and HGMD at the time of reporting; formal ACMG
      classification was VUS, with pathogenicity supported by co-segregation and
      in silico structural modelling rather than by functional assays.
    gene:
      preferred_term: MRPL44
      term:
        id: hgnc:16650
        label: MRPL44
    clinical_significance: UNCERTAIN_SIGNIFICANCE
    evidence:
    - reference: PMID:40402202
      reference_title: "A novel likely pathogenic variant in the mitochondrial ribosomal protein L44 (MRPL44) associated with hypertrophic cardiomyopathy in Tunisian patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The proband harboured a homozygous variant, NM_022915.5: c.198_205delinsTA; p.(Trp66_His69 delinsCysAsn), in the MRPL44 gene, leading to a shorter protein."
      explanation: Reports the novel Tunisian allele.
    - reference: PMID:40402202
      reference_title: "A novel likely pathogenic variant in the mitochondrial ribosomal protein L44 (MRPL44) associated with hypertrophic cardiomyopathy in Tunisian patients."
      supports: PARTIAL
      evidence_source: COMPUTATIONAL
      snippet: "In silico analysis showed significant structural differences in the mutated mL44 protein, disrupting its interaction with ribosomal complex components and impairing translation and protein synthesis."
      explanation: >-
        Pathogenicity rests on in silico modelling rather than functional assay,
        so the mechanistic claim is scored PARTIAL.
    - reference: PMID:40402202
      reference_title: "A novel likely pathogenic variant in the mitochondrial ribosomal protein L44 (MRPL44) associated with hypertrophic cardiomyopathy in Tunisian patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This variant is novel, being absent in ClinVar and Human Gene Mutation Database (HGMD) and classified as VUS according to American College of Medical Genetics and Genomics (ACMG) criteria."
      explanation: Records the formal ACMG classification as VUS.
  evidence:
  - reference: PMID:30384889
    reference_title: "Genetic Basis of Severe Childhood-Onset Cardiomyopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease genes converge on metabolic causes (PRKAG2, MRPL44, AARS2, HADHB, DNAJC19, PPA2, TAZ, BAG3), MAPK pathways (HRAS, PTPN11, RAF1, TAB2), development (NEK8 and TBX20), calcium signaling (JPH2, CALM1, CACNA1C), and the sarcomeric contraction cycle (TNNC1, TNNI3, ACTC1, MYH7, NRAP)."
    explanation: >-
      A countrywide severe childhood cardiomyopathy cohort places MRPL44 among the
      established metabolic cardiomyopathy genes.
differential_diagnoses:
- name: MRPL3-related combined oxidative phosphorylation deficiency (COXPD9)
  disease_term:
    preferred_term: Combined oxidative phosphorylation defect type 9
    term:
      id: MONDO:0013811
      label: combined oxidative phosphorylation defect type 9
  description: >-
    The closest mimic. MRPL3 encodes another protein of the same large (39S)
    mitoribosomal subunit, so COXPD9 shares the exact mechanism - a mitoribosomal
    translation defect - and presents with infantile-onset severe hypertrophic
    cardiomyopathy, failure to thrive, raised lactate, abnormal liver enzymes and
    a combined respiratory chain deficiency.
  distinguishing_features:
  - >-
    Only molecular testing separates them reliably. COXPD9 characteristically
    involves complexes I, III, IV and V, whereas MRPL44 deficiency shows the
    complex I and IV emphasis; COXPD9 also features prominent psychomotor delay
    and hepatomegaly from infancy, while MRPL44 cognition is typically normal in
    infancy with neurological features deferred to the second and third decades.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of these, cardiomyopathy has for instance been described in the following genes: AARS2, YARS2, GARS, KARS, MRPL3, MRPS22, MRPS14, MRPL44, TSFM, RMND1, MTO1, HSD17B10, ELAC2, TRMT5, GTPBP3 [3]."
    explanation: >-
      Lists MRPL3 alongside MRPL44 among the mitochondrial translation genes
      causing cardiomyopathy.
- name: MTO1 deficiency (mitochondrial hypertrophic cardiomyopathy with lactic acidosis)
  disease_term:
    preferred_term: Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency
    term:
      id: MONDO:0013865
      label: mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency
  description: >-
    A mitochondrial tRNA-modification (rather than mitoribosomal structural)
    translation defect presenting with infantile hypertrophic cardiomyopathy and
    lactic acidosis. Clinically near-indistinguishable from MRPL44 deficiency at
    presentation, and a documented source of named-entity confusion in the
    literature and in automated curation.
  distinguishing_features:
  - >-
    Molecular. MTO1 acts on mt-tRNA taurinomethyl modification, not on the 39S
    subunit; lactic acidosis is typically more severe and more consistently
    present in MTO1 deficiency, and MTO1 patients more often show early
    encephalopathy.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of these, cardiomyopathy has for instance been described in the following genes: AARS2, YARS2, GARS, KARS, MRPL3, MRPS22, MRPS14, MRPL44, TSFM, RMND1, MTO1, HSD17B10, ELAC2, TRMT5, GTPBP3 [3]."
    explanation: Lists MTO1 among the mitochondrial translation cardiomyopathy genes.
- name: Other mitochondrial translation-defect cardiomyopathies
  description: >-
    A broader group of nuclear mitochondrial translation genes causes
    biochemically indistinguishable infantile cardiomyopathy with combined
    respiratory chain deficiency: aminoacyl-tRNA synthetases (AARS2, YARS2, GARS,
    KARS), other mitoribosomal proteins (MRPS22, MRPS14), elongation and assembly
    factors (TSFM, RMND1), and tRNA-modifying enzymes (ELAC2, TRMT5, GTPBP3,
    HSD17B10).
  distinguishing_features:
  - >-
    Not separable on respiratory chain enzymology or muscle histology; requires a
    nuclear mitochondrial gene panel, exome, or genome. This is the practical
    argument for not stopping at a targeted cardiomyopathy panel.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of these, cardiomyopathy has for instance been described in the following genes: AARS2, YARS2, GARS, KARS, MRPL3, MRPS22, MRPS14, MRPL44, TSFM, RMND1, MTO1, HSD17B10, ELAC2, TRMT5, GTPBP3 [3]."
    explanation: >-
      Enumerates the mitochondrial translation genes in which cardiomyopathy has
      been described, defining this differential group.
- name: SLC25A3-related cardiomyopathy-hypotonia-lactic acidosis syndrome
  disease_term:
    preferred_term: Cardiomyopathy-hypotonia-lactic acidosis syndrome
    term:
      id: MONDO:0012557
      label: cardiomyopathy-hypotonia-lactic acidosis syndrome
  description: >-
    Mitochondrial phosphate-carrier deficiency presenting with infantile
    hypertrophic cardiomyopathy, hypotonia, and lactic acidosis - overlapping the
    MRPL44 infantile presentation closely enough to be a recognized confusable
    entity.
  distinguishing_features:
  - >-
    Mechanistically distinct: a solute-carrier (substrate import) defect rather
    than a translation defect, so mitochondrial protein synthesis and
    mitoribosome assembly are normal and the respiratory chain deficiency pattern
    differs. Marked hypotonia is a more prominent early feature.
- name: Non-mitochondrial metabolic and sarcomeric infantile cardiomyopathies
  description: >-
    Pompe disease (glycogen storage disease II), Barth syndrome (TAZ),
    fatty-acid-oxidation defects, and primary sarcomeric hypertrophic
    cardiomyopathy all present with infantile or childhood hypertrophic
    cardiomyopathy.
  distinguishing_features:
  - >-
    These are separable without sequencing: Pompe by acid alpha-glucosidase
    enzyme assay and marked creatine kinase elevation; Barth by cyclic
    3-methylglutaconic aciduria, neutropenia and X-linked inheritance;
    fatty-acid-oxidation defects by a diagnostic acylcarnitine profile; sarcomeric
    HCM by dominant inheritance, later onset, and the absence of lactic acidosis
    or combined respiratory chain deficiency.
diagnosis:
- name: Molecular genetic testing of MRPL44
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  description: >-
    Diagnosis is molecular. Every reported case was solved by exome sequencing or
    a nuclear mitochondrial-disease/cardiomyopathy panel that includes MRPL44;
    notably, a targeted comprehensive cardiomyopathy panel was non-diagnostic in
    one infant, so a mitochondrial-inclusive panel or trio exome is preferred.
    When a homozygous variant appears with only one carrier parent, add
    short-tandem-repeat and SNP-microarray testing for uniparental disomy.
  results: >-
    Biallelic (homozygous or compound heterozygous) pathogenic MRPL44 variants
    confirm the diagnosis.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical exome sequencing demonstrated compound heterozygosity for pathogenic variants in the MRPL44 gene"
    explanation: Documents exome sequencing as the confirmatory diagnostic test.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a comprehensive cardiomyopathy sequencing panel did not report any variants."
    explanation: >-
      Important diagnostic caveat - a standard cardiomyopathy gene panel missed
      the diagnosis, arguing for exome or a mitochondrial-inclusive panel.
- name: Respiratory chain enzymology of heart and skeletal muscle
  diagnosis_term:
    preferred_term: respiratory chain enzyme assay
  description: >-
    Spectrophotometric respiratory chain enzyme activities showing a combined
    complex I and IV deficiency support the diagnosis, but the yield is strongly
    tissue-dependent: the defect is profound in myocardium, intermediate in
    skeletal muscle, and only borderline in fibroblasts. A normal fibroblast
    whole-cell homogenate does NOT exclude MRPL44 deficiency - in one patient the
    complex IV deficit was apparent only in a mitochondrial isolate.
  results: >-
    Combined deficiency of complexes I and IV, most marked in cardiac tissue.
  evidence:
  - reference: PMID:23315540
    reference_title: "Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of respiratory chain enzymes revealed a combined deficiency of complexes I and IV in the heart and skeletal muscle."
    explanation: Establishes the diagnostic biochemical signature.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In fibroblasts the respiratory chain enzyme activities were normal in the 600 × g homogenate, but showed low complex IV activity in a mitochondrial isolate."
    explanation: >-
      Documents the false-negative risk of fibroblast whole-homogenate
      enzymology.
- name: Skeletal muscle biopsy with mitochondrial histochemistry
  diagnosis_term:
    preferred_term: muscle biopsy
    term:
      id: NCIT:C51895
      label: Muscle Biopsy
  description: >-
    Muscle biopsy shows ultrastructurally abnormal mitochondria, but the routine
    mitochondrial-myopathy histochemical markers can be entirely absent, so a
    normal Gomori trichrome and COX stain does not exclude the diagnosis.
  results: >-
    Abnormal mitochondria with granular content and abnormal cristae, without
    ragged red/blue fibers and without COX-negative fibers.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gomori trichrome staining did not reveal ragged blue fibers, and there were no cytochrome c oxidase negative fibers."
    explanation: >-
      Establishes that the standard mitochondrial myopathy histochemical markers
      may be absent in MRPL44 deficiency.
- name: Mitochondrial protein synthesis (translation) assay
  diagnosis_term:
    preferred_term: mitochondrial translation assay
  description: >-
    A specialist functional assay measuring 35S-amino-acid incorporation into
    mtDNA-encoded polypeptides in patient fibroblasts. It both confirms the
    translation defect and grades allele severity, which is useful for
    classifying novel MRPL44 variants.
  results: >-
    Reduced incorporation of labelled amino acids into mtDNA-encoded
    polypeptides, proportional to the severity of the genotype.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The degree of oxidative phosphorylation dysfunction correlated with the impairment of mitochondrial protein synthesis due to different pathogenic variants."
    explanation: >-
      Supports the translation assay as a genotype-severity readout usable for
      variant interpretation.
- name: Echocardiography
  diagnosis_term:
    preferred_term: echocardiography
    term:
      id: NCIT:C16525
      label: Echocardiography Test
  description: >-
    Echocardiography establishes and monitors the defining cardiac phenotype and
    is the basis for surveillance in at-risk siblings and in survivors of the
    infantile presentation.
  results: >-
    Left ventricular hypertrophy with variably depressed ejection fraction.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an echocardiogram revealed an ejection fraction of 25% (normal 55–70%) with left ventricular dysfunction and hypertrophy"
    explanation: Documents the echocardiographic findings that define the cardiac phenotype.
treatments:
- name: Supportive Heart Failure Management
  description: >
    No disease-modifying therapy exists. Care is supportive and cardiac-directed:
    beta blockade and standard anti-failure pharmacotherapy, nutritional support
    via nasogastric or gastrostomy feeding, avoidance of catabolic stress, and
    surveillance echocardiography. Intercurrent infection is a recognized trigger
    of fatal cardiac decompensation.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient responded well to treatment and was discharged at 71 days of life while being treated with beta blockers and receiving feeding mainly via gastrostomy tube."
    explanation: >-
      Documents beta blockade and enteral nutritional support as the initial
      management, with initial clinical response.
- name: Beta Blocker Therapy
  description: >
    Beta blockade is the specific anti-failure pharmacotherapy documented in
    MRPL44 deficiency; an affected infant was discharged on beta blockers with
    gastrostomy feeding after an initial clinical response, although the
    cardiomyopathy later decompensated fatally.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: beta-adrenergic antagonist
      term:
        id: NCIT:C29576
        label: Beta-Adrenergic Antagonist
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient responded well to treatment and was discharged at 71 days of life while being treated with beta blockers and receiving feeding mainly via gastrostomy tube."
    explanation: >-
      Documents beta blockade in an affected infant with an initial response.
      Scored PARTIAL - this is single-case, uncontrolled use extrapolated from
      general pediatric heart failure practice, not MRPL44-specific efficacy data.
- name: Genetic Counseling
  description: >
    Autosomal recessive counselling with a specific caveat: one reported patient
    was homozygous through complete maternal uniparental isodisomy of chromosome
    2 rather than biparental transmission. A homozygous MRPL44 result with only
    one carrier parent should therefore prompt uniparental disomy testing, since
    the recurrence risk differs substantially from the standard 25%.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:33742325
    reference_title: "Uniparental isodisomy of chromosome 2 causing MRPL44-related multisystem mitochondrial disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Short-tandem repeat and genome-wide SNP microarray analyses of the family trio confirmed complete maternal uniparental isodisomy of chromosome 2."
    explanation: >-
      Establishes uniparental isodisomy as a documented route to homozygosity in
      MRPL44 disease, which directly changes recurrence-risk counselling.
- name: Mechanical Circulatory Support
  description: >
    Ventricular assist device placement and venoarterial extracorporeal membrane
    oxygenation have been used aggressively in infants with MRPL44-related
    cardiogenic shock, on the rationale that some patients stabilize after the
    first year. In the published case this did not prevent death from multiorgan
    failure and opportunistic infection, so the benefit is unproven.
  treatment_term:
    preferred_term: ventricular assist device placement
    term:
      id: NCIT:C80452
      label: Ventricular Assist Device Placement
  therapeutic_modality: DEVICE
  target_mechanisms:
  - target: Progressive Heart Failure
    treatment_effect: INHIBITS
    description: >-
      Mechanical unloading substitutes for the failing bioenergetically depleted
      myocardium; it does not correct the underlying translation defect.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "aggressive management including left ventricle assist device was performed in the case presented here."
    explanation: Documents the use of mechanical circulatory support and its rationale.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "She remained in cardiogenic shock and hepatic failure, and ultimately developed disseminated Candida lusitanease infection which resulted in her death two days after her first birthday."
    explanation: >-
      Shows that mechanical support did not rescue the reported infant, so
      efficacy is unestablished.
- name: Cardiac Transplantation
  description: >
    Cardiac transplantation has been explicitly considered for infantile
    MRPL44-related cardiomyopathy, since the heart bears the most severe
    biochemical defect. The counterargument, which must be discussed at the time
    of listing, is that the same OXPHOS deficiency persists in all other tissues
    and can produce progressive neurological, ophthalmological, renal, and
    hepatic disease in the second and third decades.
  treatment_term:
    preferred_term: heart transplantation
    term:
      id: NCIT:C15246
      label: Heart Transplantation
  therapeutic_modality: SURGERY
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We were considering cardiac transplantation as an option in this condition in infancy, bearing in mind that in adolescence a progressive clinical involvement including neurological symptoms may still occur."
    explanation: >-
      States both the rationale for and the principal caveat against cardiac
      transplantation in MRPL44 deficiency.
- name: Mitochondrial Biogenesis Induction (Investigational)
  description: >
    Because disease severity tracks residual mL44 abundance rather than complete
    absence of the protein, pharmacological upregulation of MRPL44 expression has
    been proposed as a rational therapeutic strategy - specifically mitochondrial
    biogenesis inducers such as NRF2, PGC-1-alpha, or PPAR-delta activators. This
    is a hypothesis only: no preclinical or clinical data exist in MRPL44
    deficiency, and patient cardiomyocytes already show a spontaneous but
    ineffective mitochondrial biogenesis response, which tempers the rationale.
  treatment_term:
    preferred_term: investigational pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Biallelic MRPL44 Loss of Function and mL44 Protein Depletion
    treatment_effect: INHIBITS
    description: >-
      Raising MRPL44 transcription is proposed to partially compensate for the
      reduced steady-state abundance of the destabilized mL44 protein.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Since the amount of residual activity is related to translational efficiency, to improve the function and perhaps allow infants to recover from the cardiac dysfunction, increasing the amount of ml44 should be considered."
    explanation: >-
      States the therapeutic hypothesis. Scored PARTIAL because the paper
      proposes but does not test this strategy.
  - reference: DOI:10.1101/2025.09.24.678132
    reference_title: "Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model."
    supports: PARTIAL
    evidence_source: IN_VITRO
    snippet: "MRPL44 deficiency impairs mitochondrial translation but induces mtDNA replication and transcription in iPSC-derived cardiomyocytes."
    explanation: >-
      Tempers the biogenesis-induction rationale - patient cardiomyocytes already
      mount a biogenesis response that fails to correct the translation block.
      Preprint, in vitro.
discussions:
- discussion_id: gap_disproportionate_complex_iv_deficiency
  prompt: >-
    Why is complex IV activity disproportionately reduced relative to complex I
    in MRPL44 deficiency, when the measured synthesis rates of complex I and
    complex IV mtDNA-encoded subunits are similarly depressed and complex I has
    more than twice as many mtDNA-encoded subunits?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Mitochondrial Translation
  - pathophysiology#Combined Complex I and IV Deficiency
  rationale: >-
    In most mitochondrial transcription and translation defects, complex I (seven
    mtDNA-encoded subunits) is more affected than complex IV (three) simply
    through subunit stoichiometry. MRPL44 deficiency inverts this, as do LRPPRC
    and TACO1 disease. The 2021 functional study excluded the obvious explanation
    by showing that the newly synthesized complex IV subunits (MT-CO1, MT-CO2,
    MT-CO3) were reduced to approximately the same degree as complex I subunits
    (average 30.1% versus 34.3% of controls, not significantly different). A
    difference in post-synthetic stability of the assembled subunits was proposed
    but could not be excluded or confirmed. Resolving this matters because a
    complex IV-selective post-translational bottleneck would be a different
    therapeutic target from generic mitoribosome insufficiency.
  proposed_experiments:
  - experiment_id: exp_mrpl44_cox_subunit_pulse_chase
    name: Pulse-chase stability assay of mtDNA-encoded complex IV versus complex I subunits
    description: >-
      In MRPL44-patient and isogenic corrected cardiomyocytes, perform 35S
      pulse-chase labelling with quantification of the decay rate of newly
      synthesized MT-CO1/2/3 versus MT-ND subunits, to test whether the excess
      complex IV deficit arises from accelerated degradation of unassembled
      cytochrome c oxidase subunits rather than from unequal synthesis.
    experiment_type:
      preferred_term: pulse-chase protein stability assay
    model_systems:
    - name: Patient iPSC-derived cardiomyocyte
      description: >-
        MRPL44-mutant patient iPSC-derived cardiomyocytes with isogenic corrected
        controls, providing the human cardiac context where the biochemical defect
        is most severe.
      experimental_model_type: OTHER
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The reason for this more pronounced defect in complex IV is not clear."
    explanation: The authors explicitly state that this mechanistic question is unresolved.
- discussion_id: mismatch_yeast_mrpl3_l156r_equivalent
  prompt: >-
    Can the yeast MrpL3/mL44 homolog or a mouse Mrpl44 knockout serve as a valid
    model for human MRPL44 disease alleles, given that the human disease mutation
    modelled at the equivalent yeast residue does not impair function and that
    mouse null loss is embryonically lethal?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Biallelic MRPL44 Loss of Function and mL44 Protein Depletion
  - pathophysiology#Large Mitoribosomal Subunit Assembly Defect
  rationale: >-
    Yeast MrpL3/mL44 is the tractable genetic model for mL44 function, and
    mutagenesis of its conserved hydrophobic pocket does identify residues
    critical for assembling translationally active mitoribosomes. However, the
    exact human disease substitution modelled at the equivalent yeast residue
    (A186) had no major functional impact, and the authors concluded the two
    orthologs have diverged in evolution. Mouse Mrpl44 loss is a different kind of
    mismatch: knockout is embryonically lethal, whereas human patients carry
    hypomorphic alleles with residual protein and survive with tissue-restricted
    disease. Neither model therefore reproduces the human hypomorphic,
    cardiac-selective genotype-phenotype relationship, and both should be treated
    as tools for general mitoribosome biology rather than as MRPL44 disease
    models. Patient-derived iPSC cardiomyocytes are the emerging replacement, but
    the only published line covers a single genotype and the work remains a
    preprint.
  proposed_experiments:
  - experiment_id: exp_mrpl44_isogenic_ipsc_cardiomyocyte
    name: Isogenic MRPL44 iPSC-derived cardiomyocyte allelic series
    description: >-
      Engineer an allelic series (p.Leu156Arg, p.Leu156Pro, p.Thr161Serfs*2, and
      corrected wild type) in a common human iPSC background, differentiate to
      cardiomyocytes, and quantify mL44 abundance, 39S assembly, mitochondrial
      translation, complex I and IV activity, and contractile function, testing
      whether the human cardiac context reproduces the allele-severity gradient
      that neither yeast nor mouse captures.
    experiment_type:
      preferred_term: isogenic iPSC-derived cardiomyocyte allelic series
    model_systems:
    - name: Human iPSC-derived cardiomyocyte
      description: >-
        Cardiomyocytes differentiated from gene-edited human iPSCs carrying the
        reported MRPL44 disease alleles, preserving the human sequence context
        that diverges from yeast MrpL3.
      experimental_model_type: OTHER
  evidence:
  - reference: PMID:38950860
    reference_title: "Importance of conserved hydrophobic pocket region in yeast mitoribosomal mL44 protein for mitotranslation and transcript preference."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the introduction of the disease-related mutation into the equivalent position in the yeast protein (residue A186) was found to not have a major impact on function"
    explanation: >-
      Directly demonstrates that the yeast ortholog does not phenocopy the human
      disease allele.
  - reference: PMID:38950860
    reference_title: "Importance of conserved hydrophobic pocket region in yeast mitoribosomal mL44 protein for mitotranslation and transcript preference."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The human and yeast mL44 proteins share many similarities in sequence and structure; however results presented here indicate that these two proteins have diverged somewhat in evolution."
    explanation: The authors themselves flag the evolutionary divergence limiting model validity.
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In mice, it is expressed widely throughout multiple tissues during development and its absence is embryonically lethal"
    explanation: >-
      Mouse null lethality contrasts with the survivable, tissue-restricted human
      hypomorphic phenotype, the second arm of the model mismatch.
- discussion_id: gap_cardiac_tissue_selectivity
  prompt: >-
    What determines the striking tissue gradient of MRPL44 deficiency, in which
    heart muscle shows profound respiratory chain deficiency, skeletal muscle
    intermediate, and fibroblasts only borderline changes, despite comparable
    reduction of mL44 protein in all three tissues?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Cardiomyocyte Bioenergetic Failure and Mitochondrial Proliferation
  rationale: >-
    mL44 protein levels are reduced in heart, skeletal muscle, and fibroblasts
    alike, yet the enzymatic and clinical consequences are overwhelmingly
    cardiac. Candidate explanations include the higher OXPHOS flux demand and
    mitochondrial density of the myocardium, the postnatal switch to fatty-acid
    oxidation (the nutrient-dependent hypothesis), tissue-specific differences in
    mitoribosome assembly-factor buffering, and a possible transcript hierarchy in
    mitochondrial translation - the yeast work showed that MrpL3/mL44 mutation
    does not affect all mtDNA-encoded transcripts equally. Distinguishing a
    threshold effect from a genuinely cardiac-specific mechanism is required
    before extrapolating any therapy tested in fibroblasts to the heart.
  evidence:
  - reference: PMID:34140213
    reference_title: "Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There are tissue specific differences. The enzyme deficiency was most pronounced in cardiac muscle tissue, where there was massive proliferation of mitochondria on electron microscopy displacing contractile elements."
    explanation: Documents the tissue gradient that this gap seeks to explain.
  - reference: PMID:38950860
    reference_title: "Importance of conserved hydrophobic pocket region in yeast mitoribosomal mL44 protein for mitotranslation and transcript preference."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "we observed that mutation of the MrpL3/mL44 does not impact the translation of all mitochondrial encoded proteins equally, suggesting the mitochondrial translation system may exhibit a transcript hierarchy and prioritization."
    explanation: >-
      Offers a candidate mechanism (transcript hierarchy) for differential
      consequences, though demonstrated in yeast rather than human tissue.
- discussion_id: gap_nutrient_dependent_hypothesis_validation
  prompt: >-
    Does the postnatal glucose-to-fatty-acid fuel switch causally trigger
    MRPL44 hypertrophic cardiomyopathy in vivo, and does the ISRmt/lipid-handling
    arm represent a tractable therapeutic target distinct from OXPHOS repletion?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Nutrient-Dependent Metabolic Stress Response in Cardiomyocytes
  rationale: >-
    The nutrient-dependent model is currently supported by a single unreviewed
    preprint using one patient iPSC line in short-term culture, with immature
    in-vitro cardiomyocyte physiology. It is mechanistically attractive because it
    would explain the otherwise puzzling perinatal timing of disease onset, and
    because it points to a stress-signalling rather than purely bioenergetic
    target. It must not, however, be translated into fat restriction, ketogenic
    diet, or any other dietary manipulation: no clinical evidence supports this,
    and fasting/catabolic stress is itself a recognized hazard in mitochondrial
    disease. Replication across genotypes, in matured or engineered heart tissue,
    and ideally in vivo is required.
  proposed_experiments:
  - experiment_id: exp_mrpl44_fuel_switch_replication
    name: Multi-genotype nutrient-switch replication in matured cardiac tissue
    description: >-
      Replicate the glucose-versus-lipid comparison across at least three MRPL44
      genotypes plus isogenic controls in maturation-promoted engineered heart
      tissue, with longitudinal transcriptomics, lipidomics, contractile force,
      and ISRmt readouts, and test whether pharmacological ISRmt attenuation
      rescues the lipid-condition phenotype.
    experiment_type:
      preferred_term: engineered heart tissue nutrient-switch assay
    model_systems:
    - name: Engineered human heart tissue
      description: >-
        Maturation-promoted 3D engineered heart tissue from MRPL44-mutant and
        isogenic control iPSCs, addressing the immaturity limitation of monolayer
        iPSC cardiomyocytes.
      experimental_model_type: OTHER
  evidence:
  - reference: DOI:10.1101/2025.09.24.678132
    reference_title: "Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our findings indicate that glucose and lipids, the latter being the postnatally favored cardiac fuel, exert remarkably different consequences in MRPL44 deficient cardiomyocytes."
    explanation: >-
      States the finding whose in-vivo validity and therapeutic tractability are
      the open question. Preprint, single patient line.

📚

References & Deep Research

References

7

PMID:23315540

Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy.

No top-level findings curated for this source.

PMID:25797485

MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy.

No top-level findings curated for this source.

PMID:34140213

Pathogenic variants in MRPL44 cause infantile cardiomyopathy due to a mitochondrial translation defect.

No top-level findings curated for this source.

PMID:33742325

Uniparental isodisomy of chromosome 2 causing MRPL44-related multisystem mitochondrial disease.

No top-level findings curated for this source.

PMID:40402202

A novel likely pathogenic variant in the mitochondrial ribosomal protein L44 (MRPL44) associated with hypertrophic cardiomyopathy in Tunisian patients.

No top-level findings curated for this source.

DOI:10.1101/2025.09.24.678132

Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model.

No top-level findings curated for this source.

PMID:20301403

Primary Mitochondrial Disorders Overview.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

MRPL44 Deficiency: Disease-Characteristics Research Report

Edison Scientific Literature 22 citations 2026-08-01T17:15:45.233192

MRPL44 Deficiency: Disease-Characteristics Research Report

Executive summary

MRPL44 deficiency is an ultra-rare, autosomal-recessive nuclear mitochondrial disorder caused by biallelic pathogenic variants in MRPL44, which encodes a protein of the mitochondrial large ribosomal subunit. Its best-established presentation is neonatal or infantile hypertrophic cardiomyopathy, although subsequent reports support a broader, slowly progressive multisystem phenotype involving skeletal muscle, liver, kidney, and central nervous system. The molecular lesion destabilizes MRPL44 and the large mitoribosomal subunit, impairs 16S mitochondrial rRNA stability and mitochondrial protein synthesis/assembly, and causes combined oxidative-phosphorylation dysfunction, particularly involving complex IV. Evidence remains limited to very few families, patient-derived cells, and recent iPSC-cardiomyocyte work; prevalence, penetrance, formal diagnostic criteria, prospective natural history, and disease-specific treatment outcomes are unavailable. (boczonadi2014mitochondriaimpairedmitochondrial pages 4-5, wang2021mitochondrialproteintranslation pages 12-13, OpenTargets Search: MRPL44 deficiency-MRPL44)

Topic	Key finding	Evidence level	Notes / unknowns
Disease identity / identifier	MRPL44-related disease is a nuclear-encoded mitochondrial translation disorder described as infantile mitochondrial/hypertrophic cardiomyopathy and as part of combined oxidative phosphorylation deficiency; Open Targets lists MONDO:0014162 “infantile hypertrophic cardiomyopathy due to MRPL44 deficiency” and association to broader combined oxidative phosphorylation deficiency (MONDO:0000732) (OpenTargets Search: MRPL44 deficiency-MRPL44, boczonadi2014mitochondriaimpairedmitochondrial pages 4-5, wang2021mitochondrialproteintranslation pages 12-13)	Review/database + direct literature linkage	A disease-specific OMIM/Orphanet identifier was not directly available in retrieved source text; avoid asserting one without primary confirmation.
Causal gene and inheritance	Causal gene: MRPL44 (mitochondrial ribosomal protein L44), a component of the mitochondrial large ribosomal subunit; reported disease mechanism is biallelic/homozygous pathogenic variation, consistent with autosomal recessive inheritance (wang2021mitochondrialproteintranslation pages 12-13, pradhan2025nutrientdependentpathologyin pages 8-11)	Direct human + review	Direct segregation details for all published families were not accessible in full text here; AR inference is supported by homozygous cases and review summaries.
Established variants	Directly retrieved variant from iPSC/model study: c.467T>G, p.Leu156Arg (p.L156R) in homozygous state (pradhan2025nutrientdependentpathologyin pages 8-11, pradhan2025nutrientdependentpathologyin pages 14-17). Reviews also summarize a homozygous p.Leu156Arg MRPL44 mutation uncovered by exome sequencing in affected siblings (wang2021mitochondrialproteintranslation pages 12-13).	Direct human + iPSC preprint + review	Additional MRPL44 variants were mentioned in unavailable or secondary sources, but should be treated as unconfirmed here because the primary full text was not available in retrieved context.
Core phenotypes	Core phenotype is neonatal/infantile hypertrophic cardiomyopathy; broader spectrum may include slowly progressive multisystem disease involving skeletal muscle, liver, kidney, and central nervous system in later reports/review summaries (boczonadi2014mitochondriaimpairedmitochondrial pages 4-5, wang2021mitochondrialproteintranslation pages 12-13, pradhan2025nutrientdependentpathologyin pages 11-14)	Direct human + review	Detailed per-patient frequencies, sex ratio, and full HPO-level breakdown were not available from accessible primary text.
Molecular defect	MRPL44 deficiency causes impaired mitochondrial translation, defective large mitoribosomal subunit assembly/stability, reduced 16S rRNA stability, and OXPHOS deficiency with particular impact on complex IV; in cardiomyocytes, complex I protein reduction, increased mtDNA copy number, and stress-response activation were observed (wang2021mitochondrialproteintranslation pages 12-13, pradhan2025nutrientdependentpathologyin pages 8-11, pradhan2025nutrientdependentpathologyin pages 11-14)	Patient-cell + iPSC preprint + review	The exact hierarchy of complex defects across tissues remains incompletely resolved from accessible primary evidence.
Diagnosis	Diagnostic approaches reported or implied include exome sequencing/genomic sequencing for MRPL44, functional follow-up in patient fibroblasts or iPSC-derived cardiomyocytes, and mitochondrial disease workup focused on respiratory chain/OXPHOS defects and cardiomyopathy assessment (wang2021mitochondrialproteintranslation pages 12-13, pradhan2025nutrientdependentpathologyin pages 8-11, pradhan2025nutrientdependentpathologyin pages 1-5)	Direct human + patient-cell + iPSC preprint	No disease-specific standardized diagnostic criteria, biomarker threshold, or screening algorithm was identified in retrieved sources.
Treatment / trials	No MRPL44-specific disease-modifying therapy or interventional clinical trial was identified; management appears supportive and phenotype-directed as for mitochondrial cardiomyopathy. A review of severe childhood cardiomyopathies noted that cardiac findings in some mitochondrial cardiomyopathies including MRPL44 may stabilize in a minority who survive early childhood (vasilescu2018geneticbasisof pages 8-9, pradhan2025nutrientdependentpathologyin pages 11-14)	Review/contextual clinical evidence	No MRPL44-targeted pharmacotherapy, gene therapy, or registered MRPL44-specific trial was found in retrieved evidence.
Epidemiology	Ultra-rare disorder with only a small number of published families/cases implied across foundational and later reports; no prevalence or incidence estimate was retrieved (wang2021mitochondrialproteintranslation pages 12-13, OpenTargets Search: MRPL44 deficiency-MRPL44)	Review/database	Population prevalence, carrier frequency, founder effects, and sex distribution are unknown from accessible evidence.
Models	Patient fibroblasts: reduced MRPL44 levels and mitoribosome/OXPHOS defects summarized in reviews; patient-derived iPSC-cardiomyocytes with homozygous p.L156R show nutrient-dependent pathology, increased mtDNA copy number, reduced complex I protein, ISRmt/ER stress, and lipid droplet accumulation in fatty-acid conditions (wang2021mitochondrialproteintranslation pages 12-13, pradhan2025nutrientdependentpathologyin pages 8-11, pradhan2025nutrientdependentpathologyin pages 11-14, pradhan2025nutrientdependentpathologyin pages 14-17)	Patient-cell + iPSC preprint	No dedicated animal model of MRPL44 deficiency was directly retrieved in accessible evidence; broader mouse-model reviews discuss mitochondrial translation disease generally, not a specific MRPL44 animal model here.

Table: This table condenses the most reliable disease-specific findings currently retrievable for MRPL44 deficiency, separating direct human and cellular evidence from review/database support. It also highlights where identifiers, epidemiology, and treatment data remain unknown or insufficiently documented.

Evidence scope and limitations

The foundational report is Carroll et al., Journal of Medical Genetics, published online January 2013, “Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy” (PMID 23315540; DOI 10.1136/jmedgenet-2012-101375). A later multisystem report is indexed under PMID 34140213. Open Targets links these publications and ClinVar records RCV000054810 and RCV000791065 to MRPL44-associated disease. Some foundational full text was not retrievable during this review; consequently, unsupported patient-level numbers, laboratory values, and variant frequencies are not reconstructed from secondary summaries. (OpenTargets Search: MRPL44 deficiency-MRPL44)

A 2025 bioRxiv preprint—outside the requested 2023–2024 priority window but currently the newest disease-specific mechanistic study—uses patient-derived iPSC cardiomyocytes. Its findings should be considered pre-peer-review evidence rather than established clinical guidance. (pradhan2025nutrientdependentpathologyin pages 8-11, pradhan2025nutrientdependentpathologyin pages 1-5)

1. Disease information

Definition and identifiers

MRPL44 deficiency is a nuclear-encoded mitochondrial translation disorder in which deficient mitochondrial ribosomal protein L44 causes defective synthesis or stabilization of mtDNA-encoded oxidative-phosphorylation proteins. The cardinal recognized phenotype is infantile mitochondrial hypertrophic cardiomyopathy. Open Targets records the specific disease as MONDO:0014162, infantile hypertrophic cardiomyopathy due to MRPL44 deficiency, and also associates MRPL44 with MONDO:0000732, combined oxidative phosphorylation deficiency. MRPL44 OMIM gene entry: 611849; this number is a gene identifier, not necessarily a distinct disease-entry number. (boczonadi2014mitochondriaimpairedmitochondrial pages 4-5, OpenTargets Search: MRPL44 deficiency-MRPL44)

Common names include:

MRPL44 deficiency;
MRPL44-related mitochondrial disease;
infantile hypertrophic cardiomyopathy due to MRPL44 deficiency;
mitochondrial infantile cardiomyopathy due to MRPL44 mutation;
MRPL44-related combined oxidative phosphorylation deficiency;
MRPL44-related multisystem mitochondrial disease.

No disease-specific ICD-10, ICD-11, or MeSH code was established in the retrieved evidence. Coding would ordinarily use broader mitochondrial-metabolism and cardiomyopathy categories. A definitive Orphanet identifier was likewise not verified.

The evidence base is aggregated from published disease-level resources but ultimately derived from a very small number of individual patients and families, not population-scale EHR data. (wang2021mitochondrialproteintranslation pages 12-13, OpenTargets Search: MRPL44 deficiency-MRPL44)

2. Etiology

Cause and genetic risk

The primary cause is a germline biallelic pathogenic MRPL44 variant, producing autosomal-recessive loss of normal protein function. The best-established allele is homozygous NM_022915-related c.467T>G, p.(Leu156Arg), also abbreviated p.L156R. Exome sequencing identified this allele in affected siblings, and the same patient-derived genotype was used in the recent iPSC-cardiomyocyte model. (pradhan2025nutrientdependentpathologyin pages 8-11, wang2021mitochondrialproteintranslation pages 12-13)

The disease mechanism is functional loss/hypomorphism rather than gain of function: p.Leu156Arg reduces MRPL44 protein stability and abundance in heart, skeletal muscle, and fibroblasts. Maternal uniparental isodisomy of chromosome 2 has also been reported as a route to homozygosity for MRPL44-related disease, demonstrating that recessive disease can occasionally arise without parental consanguinity. Open Targets links the multisystem report through PMID 34140213. (wang2021mitochondrialproteintranslation pages 12-13, OpenTargets Search: MRPL44 deficiency-MRPL44)

Other risk, protective, and gene–environment factors

No validated susceptibility loci, modifier genes, protective alleles, environmental causes, toxins, infectious triggers, sex effect, or lifestyle risk factors have been established. Family history and parental carrier status are relevant because of recessive inheritance.

The strongest gene–environment observation is experimental: lipid-enriched medium, intended to approximate the postnatal cardiac fuel environment, worsened mitochondrial and ER stress and lipid dysregulation in MRPL44-mutant cardiomyocytes compared with glucose-rich conditions. This is mechanistic evidence for nutrient-dependent expression, not evidence that dietary fat causes the disease or that clinical fat restriction is beneficial. (pradhan2025nutrientdependentpathologyin pages 1-5, pradhan2025nutrientdependentpathologyin pages 11-14)

3. Phenotypes

Because the number of documented patients is extremely small, percentages should not be assigned. “Core,” “reported,” and “possible” are more defensible frequency labels.

Phenotype	Type and temporal pattern	Evidence/frequency	Suggested HPO term
Hypertrophic cardiomyopathy	Clinical sign; neonatal/infantile onset; potentially severe and progressive	Core defining phenotype	HP:0001639 Hypertrophic cardiomyopathy
Cardiac hypertrophy/ventricular-wall thickening	Imaging/pathology manifestation	Core, accompanying HCM	HP:0001712 Left ventricular hypertrophy
Heart failure/contractile dysfunction	Symptom/sign; potentially life-threatening	Expected complication of severe infantile HCM; patient-level frequency unavailable	HP:0001635 Congestive heart failure; HP:0001645 Myocardial dysfunction
Combined respiratory-chain deficiency	Biochemical abnormality; tissue dependent	Established disease mechanism	HP:0011923 Abnormal activity of mitochondrial respiratory chain
Complex IV deficiency	Biochemical abnormality	Particularly prominent in patient-cell evidence	HP:0008347 Decreased activity of cytochrome-c oxidase
Skeletal-muscle involvement/myopathy	Clinical sign	Reported in expanded multisystem spectrum	HP:0003198 Myopathy; HP:0001324 Muscle weakness
Liver dysfunction	Clinical/laboratory abnormality	Reported in expanded spectrum	HP:0001410 Decreased liver function
Renal dysfunction	Clinical/laboratory abnormality	Reported in expanded spectrum	HP:0000083 Renal insufficiency
CNS/neurologic involvement	Neurologic signs, variably progressive	Reported in expanded spectrum; exact manifestations/frequency unresolved	Use patient-specific terms rather than a generic inferred annotation
Cardiac lipid accumulation	Histopathologic/metabolic manifestation	Reported in autopsy context and reproduced as lipid-droplet accumulation in iPSC cardiomyocytes	HP:0006565 Hepatic steatosis is not appropriate; retain as free-text cardiac lipid accumulation pending an exact HPO term

Reviews classify onset as neonatal, while newer work describes infantile-onset or early-childhood HCM. Some mitochondrial cardiomyopathy survivors, including patients in MRPL44-associated groups, may stabilize around ages 5–6 years, but the proportion and predictors are unknown. (pradhan2025nutrientdependentpathologyin pages 11-14, boczonadi2014mitochondriaimpairedmitochondrial pages 4-5, wang2021mitochondrialproteintranslation pages 12-13)

No MRPL44-specific EQ-5D, SF-36, PROMIS, developmental, or caregiver-burden studies exist. Severe heart failure, weakness, and neurologic or multiorgan dysfunction would predict substantial effects on feeding, exercise tolerance, development, hospitalization burden, and daily functioning, but these impacts have not been quantified.

4. Genetic and molecular information

Gene: MRPL44, mitochondrial ribosomal protein L44; Ensembl ENSG00000135900; OMIM 611849. MRPL44 is nuclear encoded and imported into mitochondria, where it forms part of the 39S large mitoribosomal subunit. It is among mammalian mitoribosomal proteins without a direct bacterial homolog and is positioned near the polypeptide-exit region. (boczonadi2014mitochondriaimpairedmitochondrial pages 4-5, wang2021mitochondrialproteintranslation pages 12-13, OpenTargets Search: MRPL44 deficiency-MRPL44)

Pathogenic variants

c.467T>G, p.(Leu156Arg), homozygous: established disease-associated missense allele; germline; functional consequence is destabilization/reduced abundance of MRPL44 and defective large-subunit function. It was identified by WES in affected siblings and used in patient-derived fibroblast/iPSC studies. (pradhan2025nutrientdependentpathologyin pages 8-11, wang2021mitochondrialproteintranslation pages 12-13)
Other disease-associated records exist in ClinVar, including RCV000054810 and RCV000791065, but exact HGVS descriptions and current ACMG classifications were not recoverable from the retrieved texts and should be imported directly from current ClinVar rather than inferred. (OpenTargets Search: MRPL44 deficiency-MRPL44)

No reliable gnomAD/1000 Genomes/TOPMed allele frequencies were retrieved. No somatic MRPL44 disease mechanism, recurrent chromosomal deletion, structural rearrangement, repeat expansion, or disease-specific epigenetic lesion is established. No validated modifier gene has been identified.

5. Environmental information

No toxin, radiation, pollution, occupational exposure, smoking, alcohol, infection, or other external cause is known. MRPL44 deficiency is not infectious or transmissible.

The postnatal metabolic switch is a plausible physiologic modifier. Fetal myocardium relies more heavily on glucose and lactate, whereas postnatal heart maturation increases fatty-acid oxidation. MRPL44-mutant cardiomyocytes maintained better homeostasis in glucose but developed stronger stress responses and lipid accumulation under palmitate/oleate exposure. This observation may explain postnatal manifestation, but it does not justify an untested therapeutic diet. (pradhan2025nutrientdependentpathologyin pages 1-5, pradhan2025nutrientdependentpathologyin pages 11-14)

6. Mechanism and pathophysiology

Core causal chain

Biallelic MRPL44 variant → reduced/stable-defective MRPL44 protein → impaired assembly/stability of the 39S mitoribosomal large subunit and reduced 16S mt-rRNA stability → defective synthesis, maturation, or assembly of mtDNA-encoded OXPHOS subunits → respiratory-chain deficiency, especially complex IV and in cardiomyocytes complex I protein loss → impaired oxidative ATP generation and maladaptive metabolic signaling → preferential injury of high-energy tissues, particularly myocardium → infantile hypertrophy, myocardial dysfunction, and possible multisystem disease. (wang2021mitochondrialproteintranslation pages 12-13)

The foundational patient-cell work found that reduced MRPL44 did not uniformly abolish measured de novo mitochondrial translation; instead, it markedly disturbed large-subunit assembly, 16S rRNA stability, and stabilization/assembly of nascent proteins such as COX1. This nuance suggests a defect in ribosome integrity and cotranslational OXPHOS assembly rather than a simple complete translation shutdown. (wang2021mitochondrialproteintranslation pages 12-13)

Recent molecular profiling

In p.Leu156Arg iPSC-derived cardiomyocytes, glucose conditions produced a 2.5-fold increase in mtDNA copy number, increased mitochondrial transcripts and mitochondrial content, but markedly reduced steady-state complex-I protein. Thus, increased mtDNA replication/transcription failed to compensate for defective translation. (pradhan2025nutrientdependentpathologyin pages 8-11)

Fatty-acid conditions activated the mitochondrial integrated stress response and partial ER stress, including ATF5, TRIB3, ASNS, MTHFD2, GDF15, DDIT3, PSAT1, PSPH, CEBPG, HERPUD1, NUPR1, XBP1, CHAC1, and HSPA5. FGF21 induction was absent. Mutant cells showed increased lipid droplets, lipid uptake and cholesterol-pathway genes—including CD36, LDLR, ACSL1, HMGCR, HMGCS1, FDFT1 and SQLE—and reduced effective lipid utilization. The authors propose persistent ISRmt/mTORC1-linked anabolic signaling, oxidative stress, and possible ferroptotic vulnerability as downstream contributors to hypertrophic growth. These results come from one patient line and require replication. (pradhan2025nutrientdependentpathologyin pages 8-11, pradhan2025nutrientdependentpathologyin pages 11-14)

Ontology suggestions

GO biological process: mitochondrial translation (GO:0032543); mitochondrial ribosome assembly (GO:0061668); oxidative phosphorylation (GO:0006119); respiratory electron transport chain (GO:0022904); cellular response to oxidative stress (GO:0034599); fatty-acid beta-oxidation (GO:0006635).
GO cellular component: mitochondrion (GO:0005739); mitochondrial matrix (GO:0005759); mitochondrial large ribosomal subunit (GO:0005762); mitochondrial inner membrane (GO:0005743); respiratory-chain complex IV (GO:0045277).
Cell Ontology: cardiomyocyte (CL:0000746); skeletal-muscle cell/myocyte (CL:0000187); neuron (CL:0000540); hepatocyte (CL:0000182); kidney epithelial cell—use the specific renal lineage when known.

Immune dysregulation is not an established primary mechanism. Inflammation, autophagy, apoptosis, methylation changes, single-cell heterogeneity, spatial transcriptomics, lipidomics, and proteomics have not been characterized directly at disease-cohort scale.

7. Anatomical structures affected

The heart, especially ventricular myocardium and cardiomyocytes, is the best-established primary target. Suggested annotation: heart (UBERON:0000948), myocardium (UBERON:0002349), cardiac ventricle (UBERON:0002082), and cardiomyocyte (CL:0000746). Cardiac disease is generally bilateral/systemic rather than a lateralized lesion. (boczonadi2014mitochondriaimpairedmitochondrial pages 4-5, wang2021mitochondrialproteintranslation pages 12-13)

Potential secondary targets in multisystem disease include skeletal muscle, liver, kidney, and CNS. At the subcellular level, the primary compartment is the mitochondrial matrix/large ribosomal subunit, with downstream dysfunction at the inner mitochondrial membrane OXPHOS complexes. (wang2021mitochondrialproteintranslation pages 12-13)

8. Temporal development

Typical onset is congenital, neonatal, or within infancy. The course can be rapidly severe in infantile cardiomyopathy, but later reports broaden the phenotype to slowly progressive multisystem disease. Some surviving children with mitochondrial cardiomyopathy may undergo cardiac stabilization by approximately 5–6 years, although this is neither predictable nor equivalent to molecular remission. (pradhan2025nutrientdependentpathologyin pages 11-14, boczonadi2014mitochondriaimpairedmitochondrial pages 4-5, wang2021mitochondrialproteintranslation pages 12-13)

A proposed critical period is the perinatal shift from glucose/lactate metabolism to fatty-acid oxidation. In vitro, this transition uncovered strong MRPL44-mutant stress and lipid-storage phenotypes, making early postnatal cardiac maturation a plausible window of vulnerability. There are no formally defined stages, remission criteria, or validated intervention windows. (pradhan2025nutrientdependentpathologyin pages 1-5, pradhan2025nutrientdependentpathologyin pages 11-14)

9. Inheritance and population

Inheritance is autosomal recessive. For two confirmed carrier parents, each pregnancy has the standard Mendelian probabilities of 25% affected, 50% carrier, and 25% unaffected/non-carrier, subject to confirmation of parental genotypes. Uniparental isodisomy can create homozygosity and changes recurrence counseling because the mechanism may not be two-parent carrier transmission. (wang2021mitochondrialproteintranslation pages 12-13, OpenTargets Search: MRPL44 deficiency-MRPL44)

Penetrance has not been quantified; severe biallelic disease appears highly penetrant, but expressivity is variable between cardiomyopathy-dominant and multisystem presentations. There is no evidence for anticipation. Germline mosaicism, founder effects, carrier frequency, ethnic enrichment, geographic clustering, sex ratio, incidence, and prevalence remain unknown. Published evidence supports designation as ultra-rare, not a numerical prevalence estimate.

10. Diagnostics

Clinical and biochemical workup

Suspect MRPL44 deficiency in neonatal/infantile HCM—especially when accompanied by lactic acidosis, muscle, neurologic, hepatic, renal, or combined respiratory-chain abnormalities—or in otherwise unexplained mitochondrial multisystem disease with cardiomyopathy.

Recommended evaluation, extrapolated from mitochondrial-disease practice, includes:

Echocardiography and ECG, with cardiac MRI where clinically appropriate.
Plasma/CSF lactate and pyruvate, blood gas, glucose, liver and renal profiles, creatine kinase, amino acids, acylcarnitines, and urine organic acids. None is MRPL44-specific.
Respiratory-chain enzymology, oxygen-consumption studies, blue-native PAGE, or immunoblotting in fibroblasts or muscle when genomic findings require functional confirmation.
Large-mitoribosomal protein/16S-rRNA assessment and mitochondrial translation assays in specialist laboratories. Patient evidence supports reduced MRPL44, disturbed 39S assembly, reduced 16S-rRNA stability, and complex-IV deficiency as useful functional signatures. (wang2021mitochondrialproteintranslation pages 12-13)

Genetic testing

A comprehensive nuclear mitochondrial-disease/cardiomyopathy panel that includes MRPL44, trio WES, or WGS is preferred. WES identified the original p.Leu156Arg allele. WGS may add value for intronic, copy-number, structural, and uniparental-disomy detection. Segregation analysis and parental SNP/haplotype testing are important when homozygosity occurs unexpectedly. (pradhan2025nutrientdependentpathologyin pages 8-11, wang2021mitochondrialproteintranslation pages 12-13)

CMA and karyotyping are not first-line tests for a single-nucleotide MRPL44 disorder but may detect large copy-number changes or suggest UPD. mtDNA sequencing is useful in the differential diagnosis but will not detect a nuclear MRPL44 variant. FISH and repeat-expansion testing have no routine role.

RNA sequencing, quantitative proteomics, and patient-derived cellular assays may resolve splice variants or demonstrate mitoribosomal/OXPHOS signatures in unsolved cases; however, no validated MRPL44-specific omics diagnostic threshold exists.

Differential diagnosis and screening

Differential diagnoses include other mitochondrial-translation cardiomyopathies involving MRPL3, TSFM, TUFM, ELAC2, MTO1, GTPBP3, TRMT5, AARS2, mtDNA disorders, primary sarcomeric HCM, Pompe disease, fatty-acid oxidation defects, Barth syndrome, and other metabolic cardiomyopathies. MRPL3 and MRPL44 are both recognized causes of infantile HCM due to mitoribosomal dysfunction. (pradhan2025nutrientdependentpathologyin pages 1-5, boczonadi2014mitochondriaimpairedmitochondrial pages 4-5)

No standardized clinical diagnostic criteria or population/newborn biochemical screen exists. Targeted familial testing and cascade carrier testing are appropriate after a molecular diagnosis.

11. Outcome and prognosis

No 5-year survival, median life expectancy, mortality rate, or validated prognostic model is available. Severe infantile cardiomyopathy can be life-threatening, while surviving patients may stabilize cardiac function during childhood; broader multisystem disease can remain slowly progressive. (pradhan2025nutrientdependentpathologyin pages 11-14, wang2021mitochondrialproteintranslation pages 12-13)

Potential morbidity includes chronic heart failure, arrhythmia risk, impaired exercise tolerance, muscle weakness, neurodevelopmental or neurologic disability, and liver or kidney dysfunction. Prognosis should therefore be based on serial cardiac function, rhythm, growth, lactate/metabolic status, neurologic development, and hepatic/renal involvement rather than genotype alone. No validated prognostic biomarker has been established. GDF15 was induced in mutant cardiomyocytes under experimental conditions, but it is not validated as an MRPL44-specific clinical predictor. (pradhan2025nutrientdependentpathologyin pages 8-11)

12. Treatment

There is no approved MRPL44-specific disease-modifying therapy, gene therapy, RNA therapy, or clinical-trial intervention. The ClinicalTrials.gov search retrieved no relevant MRPL44-specific study.

Current care is supportive and multidisciplinary:

guideline-directed pediatric cardiomyopathy/heart-failure therapy and arrhythmia surveillance;
consideration of mechanical support or transplantation for refractory end-stage cardiac failure, evaluated individually because multisystem mitochondrial disease can affect candidacy;
nutritional support and avoidance of prolonged fasting/catabolic stress;
prompt treatment of infection, dehydration, and metabolic decompensation;
physical, occupational, speech, and developmental therapy as indicated;
monitoring and treatment of hepatic, renal, neurologic, hearing, vision, and endocrine complications.

Potential NCIt annotations include Supportive Care (NCIT:C15747), physical therapy, occupational therapy, cardiac transplantation, mechanical circulatory support, and genetic counseling; exact NCIt identifiers should be verified against the current terminology release.

The iPSC finding that fatty acids exacerbate cellular pathology is hypothesis-generating only. It should not be translated into ketogenic therapy, fat restriction, or another major dietary manipulation outside specialist supervision and research protocols. (pradhan2025nutrientdependentpathologyin pages 1-5, pradhan2025nutrientdependentpathologyin pages 11-14)

13. Prevention

The molecular disease cannot presently be prevented after conception by lifestyle change or immunization. Primary reproductive prevention options after identifying familial variants include carrier testing, cascade testing, preimplantation genetic testing for monogenic disease, chorionic-villus sampling, amniocentesis, donor gametes, or other family-planning choices. UPD-mediated cases require individualized recurrence assessment.

Secondary prevention consists of early molecular diagnosis and cardiac surveillance in at-risk siblings. Tertiary prevention focuses on avoiding fasting and catabolic stress, maintaining vaccination and infection prevention, monitoring organ function, and treating cardiac or metabolic deterioration promptly. MRPL44 deficiency is not currently an established population newborn-screening target; the absence of a specific, proven early treatment is a major limitation.

14. Other species and natural disease

No naturally occurring MRPL44-deficiency syndrome in companion animals, livestock, or wildlife was identified. There is no zoonotic potential or cross-species transmission. Orthologs are evolutionarily conserved across mammals, but exact NCBI Gene and NCBI Taxonomy identifiers should be imported from current organism databases rather than inferred here.

15. Model organisms and experimental systems

Patient fibroblasts

Patient fibroblasts provided the foundational functional model. They demonstrated reduced MRPL44 abundance, impaired large-mitoribosomal-subunit assembly, destabilized 16S rRNA, and complex-IV/OXPHOS abnormalities. Their limitation is that fibroblasts do not reproduce the mature myocardium’s high energy and fatty-acid demands. (wang2021mitochondrialproteintranslation pages 12-13)

Patient-derived iPSC cardiomyocytes

The principal disease-relevant model is the homozygous c.467T>G, p.Leu156Arg patient iPSC line differentiated into cardiomyocytes. More than 80–90% of differentiated cells expressed cardiac troponin T. The model reproduced mitochondrial compensation, reduced complex-I protein, nutrient-dependent ISRmt/ER stress, and lipid-droplet accumulation. It is useful for studying cardiac maturation, metabolic stress, biomarkers, and candidate interventions. Limitations include one patient genotype, immature in-vitro cardiomyocyte physiology, short exposure, and preprint status. (pradhan2025nutrientdependentpathologyin pages 8-11, pradhan2025nutrientdependentpathologyin pages 5-8)

Animal models

No dedicated MRPL44 knock-in or conditional-knockout animal model with a published, well-characterized human-disease phenotype was established in the retrieved evidence. Recent reviews emphasize that mouse models of mitochondrial translation are valuable because constitutive loss of essential translation machinery can be embryonically lethal and tissue-specific models reveal organ vulnerability; however, these general observations should not be represented as direct MRPL44 animal evidence. (hughes2024illuminatingmitochondrialtranslation pages 6-7)

Recent developments and expert interpretation

A 2024 review of defective mitochondrial protein synthesis emphasized that these diseases preferentially affect high-energy tissues and remain mechanistically heterogeneous despite advances in NGS and cryo-EM (published May 2024; DOI 10.3389/fcell.2024.1410245). A 2024 mouse-model review likewise concluded that impaired mitochondrial translation produces severe, diverse disease and that tissue-specific models are essential for therapeutic development (published May/August 2024; DOI 10.1093/hmg/ddae020). (hughes2024illuminatingmitochondrialtranslation pages 6-7, antolinezfernandez2024molecularpathwaysin pages 12-14)

The newest MRPL44-specific work proposes that OXPHOS failure alone is insufficient to explain hypertrophy. Its key abstract conclusion is that lipid-enriched conditions elicited “robust activation of metabolic stress responses” and lipid accumulation, providing a mechanistic link between the postnatal fuel transition and infantile disease manifestation. This is an important shift from a purely ATP-deficiency model toward a combined model of mitochondrial translation failure, maladaptive stress signaling, and lipid-metabolic remodeling. It remains experimental and awaits peer review, replication across genotypes, and validation in vivo. (pradhan2025nutrientdependentpathologyin pages 1-5, pradhan2025nutrientdependentpathologyin pages 11-14)

Key knowledge gaps

Exact worldwide case count, prevalence, incidence, carrier frequency, and population distribution.
Complete variant spectrum with harmonized ACMG classification and gnomAD frequencies.
Prospective natural history, survival, quality of life, and genotype–phenotype correlations.
Standardized biochemical diagnostic thresholds and validated prognostic biomarkers.
Dedicated animal models and replicated patient-specific cardiac models.
Evidence for pharmacologic, dietary, gene-replacement, RNA, or editing therapies.
Single-cell, spatial, longitudinal proteomic, metabolomic, and lipidomic studies.

Accordingly, MRPL44 deficiency should be represented in a knowledge base as a well-supported gene–disease association with a strong mechanistic basis but a very limited clinical evidence set, and unknown fields should remain explicitly null rather than be populated from broader mitochondrial-disease assumptions. (wang2021mitochondrialproteintranslation pages 12-13, OpenTargets Search: MRPL44 deficiency-MRPL44)

References

(boczonadi2014mitochondriaimpairedmitochondrial pages 4-5): Veronika Boczonadi and Rita Horvath. Mitochondria: impaired mitochondrial translation in human disease. The International Journal of Biochemistry & Cell Biology, 48:77-84, Mar 2014. URL: https://doi.org/10.1016/j.biocel.2013.12.011, doi:10.1016/j.biocel.2013.12.011. This article has 156 citations.
(wang2021mitochondrialproteintranslation pages 12-13): Fei Wang, Deyu Zhang, Dejiu Zhang, Peifeng Li, and Yanyan Gao. Mitochondrial protein translation: emerging roles and clinical significance in disease. Frontiers in Cell and Developmental Biology, Jul 2021. URL: https://doi.org/10.3389/fcell.2021.675465, doi:10.3389/fcell.2021.675465. This article has 145 citations.
(OpenTargets Search: MRPL44 deficiency-MRPL44): Open Targets Query (MRPL44 deficiency-MRPL44, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(pradhan2025nutrientdependentpathologyin pages 8-11): Swagat Pradhan, Nahid A Khan, Tuula Manninen, Aleksandra Zhaivoron, and Anu Suomalainen. Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.24.678132, doi:10.1101/2025.09.24.678132. This article has 0 citations.
(pradhan2025nutrientdependentpathologyin pages 14-17): Swagat Pradhan, Nahid A Khan, Tuula Manninen, Aleksandra Zhaivoron, and Anu Suomalainen. Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.24.678132, doi:10.1101/2025.09.24.678132. This article has 0 citations.
(pradhan2025nutrientdependentpathologyin pages 11-14): Swagat Pradhan, Nahid A Khan, Tuula Manninen, Aleksandra Zhaivoron, and Anu Suomalainen. Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.24.678132, doi:10.1101/2025.09.24.678132. This article has 0 citations.
(pradhan2025nutrientdependentpathologyin pages 1-5): Swagat Pradhan, Nahid A Khan, Tuula Manninen, Aleksandra Zhaivoron, and Anu Suomalainen. Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.24.678132, doi:10.1101/2025.09.24.678132. This article has 0 citations.
(vasilescu2018geneticbasisof pages 8-9): Catalina Vasilescu, Tiina H. Ojala, Virginia Brilhante, Simo Ojanen, Helena M. Hinterding, Eino Palin, Tero-Pekka Alastalo, Juha Koskenvuo, Anita Hiippala, Eero Jokinen, Timo Jahnukainen, Jouko Lohi, Jaana Pihkala, Tiina A. Tyni, Christopher J. Carroll, and Anu Suomalainen. Genetic basis of severe childhood-onset cardiomyopathies. Journal of the American College of Cardiology, 72 19:2324-2338, Nov 2018. URL: https://doi.org/10.1016/j.jacc.2018.08.2171, doi:10.1016/j.jacc.2018.08.2171. This article has 170 citations and is from a highest quality peer-reviewed journal.
(pradhan2025nutrientdependentpathologyin pages 5-8): Swagat Pradhan, Nahid A Khan, Tuula Manninen, Aleksandra Zhaivoron, and Anu Suomalainen. Nutrient-dependent pathology in mitochondrial hypertrophic cardiomyopathy model. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.24.678132, doi:10.1101/2025.09.24.678132. This article has 0 citations.
(hughes2024illuminatingmitochondrialtranslation pages 6-7): Laetitia A Hughes, Oliver Rackham, and Aleksandra Filipovska. Illuminating mitochondrial translation through mouse models. Human Molecular Genetics, 33:R61-R79, May 2024. URL: https://doi.org/10.1093/hmg/ddae020, doi:10.1093/hmg/ddae020. This article has 4 citations and is from a domain leading peer-reviewed journal.
(antolinezfernandez2024molecularpathwaysin pages 12-14): Álvaro Antolínez-Fernández, Paula Esteban-Ramos, Miguel Ángel Fernández-Moreno, and Paula Clemente. Molecular pathways in mitochondrial disorders due to a defective mitochondrial protein synthesis. Frontiers in Cell and Developmental Biology, May 2024. URL: https://doi.org/10.3389/fcell.2024.1410245, doi:10.3389/fcell.2024.1410245. This article has 16 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

MRPL44 Deficiency: Disease-Characteristics Research Report

Executive summary

Evidence scope and limitations

1. Disease information

Definition and identifiers

2. Etiology

Cause and genetic risk

Other risk, protective, and gene–environment factors

3. Phenotypes

4. Genetic and molecular information

Pathogenic variants

5. Environmental information

6. Mechanism and pathophysiology

Core causal chain

Recent molecular profiling

Ontology suggestions

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Clinical and biochemical workup

Genetic testing

Differential diagnosis and screening

11. Outcome and prognosis

12. Treatment

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Patient fibroblasts

Patient-derived iPSC cardiomyocytes

Animal models

Recent developments and expert interpretation

Key knowledge gaps

Artifacts